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NOMENCLATURE
ºC: Degrees Celsius
µL: Microliter
cfu: Colony-forming Unit
kbp: Kilobase pair
kDa: KiloDalton
ml: Milliliter
RPM: Revolutions per minute
M: Molar (moles/ liter)
mM: Millimolar (milimoles/liter)
V: Voltage

ABBREVIATIONS
2’ Ab: Secondary antibody
AGID: Agar gel immunodiffusion
ASCA: anti-S. cerevisiae antibodies
CCFA: Crohn’s and Colitis Foundation of America
CD: Crohn’s Disease
CF: Complement fixation
CWD: Cell wall deficient
ELISA: Enzyme-linked immunosorbant assay
FAE: Follicle Associated Epitheleum.
FBS: Fetal Bovine Serum
FC: Flow cytometry
FCM: Flow cytometry method
FITC: Fluorescine isothiocyanate.
GALT:Gut-associated Lymphoid Tissue
GI: Gastrointestinal
HC: Healthy Controls
IBD: Inflammatory Bowel Disease
IFN-γ: Interferon gamma
IgA: Immunoglobulin A
IgG: Immunoglobulin G
p-ANCA: Atypical perinuclear anti-neutrophil cytoplasmic autoantibodies
JD(+/-): Johne’s Disease positive/negative
LAM: Lipoarabinomannan
MAA: Mycobacterium avium subsp. avium
MAP: Mycobacterium avium subsp. paratuberculosis
MHC: Major histocompatibility complex
OD: Optical density
PP: Peyer’s Patch
SEM: Scanning electron microscope
TCR: T cell-receptor
UC: Ulcerative Colitis
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Abstract
Crohn's disease is a chronic inflammatory bowel disease of
unknown origin that continues to affect millions of people worldwide.
Mycobacterium avium subsp. paratuberculosis (MAP) has been a
suspected etiological agent of Crohn’s disease for nearly two decades.
Recently, our laboratory was able to achieve a test sensitivity of 95.2%
(n=21) by using a flow cytometry method (FCM) to detect anti-MAP
antibodies in Johne’s diseased cattle. Here we investigate whether FCM
can differentiate Crohn’s patients’ antibody titers from healthy human
control antibody levels. As a second research goal, we investigated other
suspected bacteria and serum-differentiating yeast using the FCM. In
brief, bacteria/yeast were incubated with serum samples and washed to
remove nonspecific antibodies. Antibodies bound to the surface of
bacteria/yeast were then labeled with fluorescently-tagged secondary
antibody and this binding evaluated by flow cytometry. Serum samples
from 37 Crohn’s patients and 37 healthy human controls were tested for
antibody (IgG and IgA) binding to bacteria/yeast. When targeting
antibodies directed towards MAP, no significant difference was observed
between the two populations (ANOVA, alpha=0.05). FCM was also
unable to detect an antibody response for either group when directed
against a cell-wall-deficient form of MAP, which has been reported to be
near infected tissues of Crohn’s diseased patients. However, a differential
antibody response to two yeasts that included S. cerevisiae and C. albicans
was detected when looking for both IgG and IgA. This differentiation
using yeast agrees with previous studies that have shown Crohn’s diseased
subjects to have significantly higher antibody titers to this yeast than do
healthy controls. This suggests that the flow cytometry method could be
useful in the future for distinguishing Crohn’s subjects from healthy
controls.
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CHAPTER I: SCOPE AND OBJECTIVES OF STUDY
Since its’ first description in the early 20th century Crohn’s disease (CD)
has continued to confuse investigators and doctors alike, as the exact cause for
CD has yet to be fully described. Since 1984, when Mycobacterium avium subsp.
paratuberculosis (MAP) was first cultured from the inflamed intestinal tissue of
three Crohn’s diseased patients [1], the possibility of there being a bacterial
etiology for Crohn’s disease has been under intense scrutiny . This question
remains unresolved; however the plethora of research on the topic includes many
findings that indicate MAP as an agent of CD. It is of great importance to note
that MAP is shed in the milk of dairy cows with Johne's disease (JD) and can
survive the pasteurization process. Thus, there is an immediate need to study the
involvement of this potentially zoonotic bacterium in the pathogenesis of Crohn’s
disease. Yet, a consistently sensitive test for MAP is lacking even for JD-infected
animals.
In 2005, our lab was able to differentiate populations of JD-infected and
JD-negative dairy cattle using a novel detection method that utilized a Flow
cytometer. We obtained a sensitivity of 95%, which was considerably higher than
commercially available diagnostic ELISAs that typically having sensitivities in
the 15-30% range [2]. The method differs from these ELISAs in that it uses
whole-cell MAP and therefore is able to detect antibodies directed against an
array of MAP surface antigens. Our primary objective in this study was to
investigate the prevalence MAP-directed antibodies in Crohn’s diseased subjects
and healthy controls. We would utilize a similar technique to that used in the JD
studies. Since MAP is not the only bacterial suspect to cause CD, we also
investigated other bacteria as a secondary objective. The method is universally
designed to work for any bacteria and could be performed on any of these
suspects. Our third objective was to investigate antibodies directed to certain
yeast species which have been known to improve the diagnostic prognosis of CD
from other similar inflammatory bowel diseases. If our method could increase the
sensitivity of this test, those with unknown IBD could be more accurately
diagnosed and begin receiving the appropriate treatments.

1

CHAPTER II: BACKGROUND
General Information on Crohn’s Disease
An Introduction to Crohn’s Disease
Crohn’s disease (CD) is a chronic debilitating inflammatory bowel disease
that affects millions of people each year. The disease is named for Dr. Burrill B.
Crohn, one of three authors to first describe the disease in 1932 [3]. In America
alone, the disease is believed to affect about a million individuals according to
The Crohn’s and Colitis Foundation of America (CCFA) [4]. Interestingly,
developed countries seemed to be more prone to high CD prevalences within their
populations, but Western Europe and the United States seem to be particularly
vulnerable [5].
Crohn’s Disease is a member of a broad group of inflammatory bowel
diseases (IBDs) of unknown origin occurring in the gastrointestinal (GI) region.
The similarities between CD and a second IBD called ulcerative colitis (UC) are
striking and thus a differential diagnosis can often be difficult. CD inflamed
tissue regions can occur at nearly any region of the GI tract, but nearly 70% of
those infected with CD will have granulomatous legions of inflamed tissue in the
small intestine or the junction region of the cecum [6]. Diseased tissue is often
described as cobblestoned with patches of healthy intestinal lumen often
interrupting diseased portions [7]. Patients stricken with CD often experience
bouts of stomach pain and have their lives severely affected by the
unpredictability of their digestive system, a continuous malaise, and the
coexisting malnutrition which often occurs. Severe weight loss and diarrhea are
common signs that CD may be setting in [7].
In about 50% of CD patients, inflammations can become severe enough to
bring about a blockage (stenosis) that requires surgery [6]. The Crohn’s and
Colitis Foundation of America estimates that, overtime, nearly two-thirds of CD
patients will require a surgery to relieve a disease symptom. One common
surgery is the removal of blockages of the GI tract caused by extremely inflamed
tissue [8]. Another is the removal of fistulas, which are regions of the intestine
that have become connected with other, unintended organs and are leaking GI
constituents to these organs [8]. An average of 25% of CD patients are expected
to have such fistulas [8]. The bladder, the vagina, as well as other portions of the
GI tract are commonly connected by such fistulas. Internal bleeding within the
intestines is a third disease severity which often calls for surgery. About 5% of
CD patients develop other more obscure symptoms like eye, skin, or joint
inflammations due to CD onset [7].
Disease onset generally occurs in those 16-25 years of age but has also
been seen to occur both in early childhood and late adulthood [9]. There is no
standard method for diagnosing CD and a plethora of tools are generally used.
The average wait time for specific diagnosis after presenting symptoms was
recently reported to be 2 years [6]. Diagnostic approaches include X-ray
2

methods, endoscopy, biopsy, stool examination, and a family history check [8].
There is no cure for CD, only pharmaceuticals to relieve symptoms and severity
of disease. Of the many treatments available general immunosuppressants are
used for severe cases of CD. This is because immunosuppressants in the form of
steroids tend to weaken the immune systems ability to fight other pathogens
which is a dangerous venture. Anti-inflammatories are very popular treatment
choices for CD patients who have more moderate symptoms. Antibiotics are also
commonly administered to aide the downgraded immune system in fighting
infections.
The Three Main Crohn’s Disease Etiological Theories
The name “Crohn’s disease” is often described as a misnomer as it may be
better characterized as a syndrome, rather than a specific disease. Disease often
entails a single causative agent. In CD, this etiological agent has yet to be fully
proven [7]. Since its description in the 1930’s, a rigorous search for the root
cause of CD has raged on. To this end, three main theories have emerged. The
two noninfectious theories include an autoimmune theory and the genetic
predisposition theory.
Since many other chronic inflammatory responses are considered to be
autoimmune diseases (rheumatoid arthritis, diabetes mellitus type 1, etc) it is not
hard to see why some have favored an autoimmune theory for CD. This focuses
on the overactive immune responses to what many consider to be self-antigens. It
is supported by evidence of manifestations of disease that are outside of the GI
tract, such as the rheumatoid arthritis and other inflammations that can also occur
with CD. It is further supported by the extreme effectiveness of antiinflammatory agents which are effective on immune responses. CD subjects
have much higher titers of IL-12, IFN-γ, and TNF-α which are all hallmark
cytokines of cell-mediated immune responses (TH1 responses) [5] Thus, many
have proposed that CD too may be of similar autoimmune etiology. That is, our
own immune cells may be triggered to attack self-cells due to an over expression
of certain inflammatory response cytokines.
The genetic predisposition theory seems to be gaining more ground as of
recently. Roughly 20% of CD patients have relatives that also carry the
symptoms of CD [7]. Twin studies show that at least 50% have of identical twins
are simultaneously affected with CD [6]. In addition, particular ethnic groups
(like the Jewish, Caucasian, and African-American communities) seem to be at a
higher risk which also seems to indicate a common genetic link to acquisition [7].
Lastly, certain mutations in particular chromosomes seem to indicate higher risk
for disease. Approximately 10-30% of CD patients have a mutated
NOD2/CARD15 gene on chromosome 16 [7, 9]. This gene is thought to be
expressed as a surface protein on human macrophages and monocytes as well as
intestinal epithelial cells [9]. In particular, the protein may interact with bacteria
and the antigens they express on their outer walls [7]. The protein is thought to
control strong pro-inflammatory responses via the cell-mediated pathway, and
3

hence mutations may delay appropriate bacterial elimination responses. One
study by Hisamatsu et al. showed intestinal epithelial cells that expressed a
mutant NOD2/CARD15 gene to be ineffective at removing a well known
foodbourne pathogen, Salmonella typhimurium [10]. It is important to note that
the NOD2/CARD15 data thus far elucidated are far from conclusive and up to 5%
of the general population may have the mutation; most of which will not develop
CD [7].
The last of the theories is that of an infectious etiology. This is the idea
that a foreign biological entity is responsible for causing the chronic inflammatory
disease. Within the granulomas of the CD-infected tissues, numerous
lymphocytes and macrophages conglomerate. Such granulomas are witnessed in
other infectious disease and hence, there is a strong suspicion that CD may
involve a similar pathway. There are a number of suspect microbial agents that
are associated with this theory [5].

Non-MAP Microbial Suspects Postulated to Cause Crohn’s Disease
An array of non-MAP bacterial suspects has been postulated to cause CD.
A number of different methods have been employed to try and prove a bacterial
association with CD. Since a number have been postulated, this review highlights
only the most convincing cases of bacterial suspects for CD. These prominent
suspects are listed in Figure 1 along with their reported prevalence upon
publication.
A study conducted by Liu et al. attempted to characterize the typical flora
found in CD patients [11]. The study examined tissue samples from CD patients.
Primary antibodies against a select group of bacteria were used to detect bacteria
presence. Positive control tissues for each probed bacteria/virus were used to
ensure the antibodies were specifically binding to the microorganisms. The
groups of tissues were diverse with some coming from Europe and others from
North America. Immunolabeling for 12 of the 16 CD tissue samples (75%) were
positive for Listeria monocytogenes, , a bacteria responsible for a large percentage
of food poisoning cases each year. In contrast, none of the tissues from healthy
individuals and those from patients with other cases of colitis
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Pathogen

Prevalence

E. coli (EIEC)

3/64 or 4.5% (Weber et al.)
12/21or 57% (Liu et al.)
11/16 or 69% (Cartun et. al)

Clostridium difficle

5/49 or 10.2% (Weber et al.)

Yersinia pseudotuberculosis

Possible association
(Homewood et al)

Yersinia entercolitica

3/41 or 7.3% (Saebo et al)

Listeria monocytogenes

12/16 or 75%

Campylobacter jejuni

1/64 or 1.5% (Weber et al.
1992)

Streptococcus gallolyticus

7/16 (44%) (Liu et al.)
from Streptococcus group F

Enterococcus faecalis (Previously Streptococcus
faecalis )

7/16 (44%) (Liu et al.)
from Streptococcus group F

(Liu et al.)

Figure 1: Microbes postulated to be associated with
Crohn’s Disease

5

showed antibody binding to Listeria monocytogenes. Most of the reactivity was
observed within macrophages, indicating host cell invasion by the bacteria. Yet,
L. monocytogenes was also shown to coexist with two specific bacteria in 10 of
the 12 tissues it was observed in. It is, therefore, possible that L. monocytogenes
was a secondary invader. Further, another study conducted by Blaser et al. was
unable to show increased antibody reactivity to the bacteria using the serum of 40
CD subjects and 40 healthy subjects [12].
The same study conducted by Liu et al. also showed a marked distinction
in E. coli reaction with an overall positive reaction of 57% [11]. For E. coli 12 of
the 21 CD tissues examined were positive for immunoreaction to E. coli antigens.
Cartun et al. also found evidence of E. coli in 69% of formalin-fixed CD tissue
[13]. These findings agreed with Tabaqchali et. al who found a higher antibody
titer to E. coli O antigens in CD subjects in comparison to healthy controls [14].
Importantly, UC subjects also showed high antibody levels to E. coli antigens and
thus, a secondary infection due to the chronic inflammation was not ruled out by
these authors.
Further, Liu et al. found a CD seroreactivity of 44% to the F group
antigens of the genus Streptococcus [11]. This finding was similar to Cartun et
al. who found that 63% of their CD serum reacted strongly to the bacterial
antigens [13]. Yet, 25% of UC subjects in the Liu study also showed a positive
immunoreactivity to these antigens indicating a lack in specificity for CD within
the IBD group [11].
In 1992, Weber et al. surveyed IBD patients’ stool samples and biopsies;
including both CD and UC subjects [15]. Out of the 49 CD patients, 5 or 10.2%
were positive for Clostridium difficile. This was the most prevalent of the several
microbes the investigators probed which also included MAP. Yet, Keighly et al.
provided evidence that C. difficile may not be involved when they noted a
spontaneous disappearance of the bacteria in CD patients’ stool when the study
continued to follow a group which had previously tested positive for the bacteria
[16]. Weber et al. also cultured a peculiar microbe well known for its role in food
poisoning in Salmonella typhimurium from the stool of a UC patient [15].
Yersinia entercolitica had been postulated as a possible suspect for UC but
not CD for years. Yet a seven year study conducted by Saebo et al. involving
1041 subjects are suggestive of some involvement of these bacteria for CD [17].
Of the 1041 subjects that were tested, only 41 of them tested positive for the
bacteria via an agglutination test. Of these, 3 of the 41 turned out to be CD
positive or 7.3%. While the prevalence rates are not as high as others that have
been reported for CD, the unexpected finding that the bacteria was found in both
UC and CD patients but not controls calls for further testing.
Campylobacter jejuni also has raised suspicions lately, after being cultured
by Weber et al. from the stool of a CD patient [15]. The common disease it is
known to cause in humans, Campylobacter jejuni enterocolitis, was also found to
share common host autoantibodies to UC and CD in a study conducted by
Berberian et al. [18]. This autoantibody directed against host red blood cells was
found to be highest in CD serum, but the Campylobacter jejuni chronically
6

infected subjects also were found to produce the autoantibody in comparable
amounts.
Yersinia pseudotuberculosis and Yersinia enterocolitica can cause
an acute terminal ileitis that can be a preceding symptom to Crohn’s
disease [19]. Others have shown elevated blood titers of the Yersinia
genus in CD patients. Homewood et al. discuss the evidence for this and
conclude that the Yersinia correlation is likely due to secondary infections
of the bacteria primed by Crohn’s like conditions.

Yeasts and Their Importance in Diagnosing Crohn’s Disease
A eukaryotic microbe that we are all familiar with in our daily lives has
also been making an impact on the diagnosis of inflammatory bowel diseases.
Yeast, both baker’s and brewer’s, is the common name for the eukaryote
Saccharomyces cerevisiae. For years food antigens were thought to play an
important role in worsening IBD symptoms. Main et al. reported the first known
antibody response to a food antibody that was specific for CD but not UC [20].
The authors probed a serum population of CD and HC for an antibody response to
baker’s yeast. A subsequent ELISA-like test utilized an isolated yeast antigen to
elicit a response. Serum populations included healthy controls, UC patients, and
CD patients. The results revealed an astoundingly strong response by CD sera
with virtually no response at all by the remaining sera populations. The marked
differences are clearly visible in Figure 2. Levels of antibody (IgG and IgA )
binding to S. cerevisiae in serum samples of CD patients were much higher than
that in control and UC groups (Figure 1).
The differentiation of the CD group from other groups was statistically
more significant when IgA against S. cerevisia was detected. Since it is often
difficult to distinguish between UC and CD, this test may offer an easy, virtually
pain-free method of determining which IBD an individual may have incurred.
Since the release of that study, a plethora of other papers differentiating sera
populations based upon yeast antigens (usually called anti-S. cerevisiae antibodies
or ASCAs) has peppered the scientific literature [21]. Most of these consist of an
ELISA format , with around 60% of the CD subjects showing an elevated
antibody response to yeast. Since only 10% of UC subjects show a similar high
response, CD-UC differentiation is possible. Further, a second differentiation is
possible because only UC patients have been shown to produce autoantibodies
against self-neutrophils (called atypical perinuclear anti-neutrophil cytoplasmic
autoantibodies or p-ANCA). The percentages detected using the p-ANCA assay
are a virtual reciprocal of those mentioned with the yeast ELISA. Thus, blood
may be drawn and both assays can help give the gastroenterologist a good
indicator of which disease may be present. It is important to note, however, that
there may be a difference in antibody production to yeast depending on one’s
country of origin. In one study conducted by Preda et al. only a low prevalence of
ASCA (12.5%, n=40) existed within the CD group of a serum population
7

Figure 2: Differentiation of serum populations based on IgG
and IgA antibody reactions to yeast (from Main et al. [20])
from Romania [22]. Another yeast, Candida albicans, has also been surveyed for
its use as a disease marker for CD. C. albicans has common surface antigens
(notably a surface polysaccharide called mannan). Thus in 2006, Standaert-Vitse
et al. were able to show that C. albicans can act as animmunogen to the ASCA
tests [23]. This is because it is able to mimic S. cerevisiae with its mannanprotein production. A second study conducted by Savage et al. showed a marked
increase in antibody production to C. albicans in CD sera as compared with
healthy controls [24]. Yet, it must be noted that an older study conducted by
McKenzie et al. found no significant difference when they tested CD subjects and
healthy controls for antibodies to C. albicans [25].
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An Overview of the Case for MAP as an Etiological Agent of Crohn’s
Disease
Presence of MAP or Antibodies Against MAP in CD patients
Of all the microbial suspects touched on above, none has garnered as
much attention as Mycobacterium avium subsp. paratuberculosis. The linkage
between MAP and Crohn’s disease is one that has been long suspected, but
received enormous attention after Chiodini et al. isolated an uncharacterized
mycobacteria from the diseased intestinal tissue of three Crohn’s patients [1].
DNA probes later revealed these mycobacteria to be MAP [26]. Interestingly,
many of the MAP particles which have been identified thriving in the intestinal
regions of infected humans have taken on a cell-wall deficient form (spheroplast)
[27]. This meant that the classical acid-fast staining used to identify mycobacteria
is not able to differentiate these microbes [28]. However, IS900 DNA probes are
still able to detect the bacteria and one in situ hybridization study by Sechi et al.
revealed that up to 70% of the Crohn’s patients tested positive for the MAP
insertion sequence [29]. A follow-up study by the same group revealed that
another 70% of CD patients were both positive for MAP by IS900 but, in
addition, were also positive for the NOD2 mutation mentioned previously [30]. In
2004 Naser et al. identified 46% of Crohn’s patients as having MAP DNA in the
buffy coat of their blood while only 10% of the healthy controls were PCR
positive [31]. Naser et. al was also able to culture MAP from the breast milk of
two CD mothers, while none of the healthy controls cultivated bacteria [32].
It must be noted, however, that IS900 PCR methods aiming to detect MAP
within Crohn’s patients have not always been as successful. While some studies
show IS900 PCR detection methods to detect the bacterium in up to 76% of
Crohn’s patients, others have found prevalence rates that hover around 30-40%
[33]. In addition, the some data revealed no significant difference between
healthy controls and Crohn’s patients. Such inconsistencies raise the possibility
of cross-reactivity of IS900 PCR primer, with the most likely candidate being the
insertion sequence derived from MAA.
Mycobacteria-derived antigen p36 tests have provided further support for
the MAP-Crohn’s connection. Naser et al. found that this antigen reacted with
86.5% of Crohn’s diseased patients and 89% of patients with leprosy or
tuberculosis [34]. Conversely, only 10% of control subjects who had not received
a BCG immunization tested positive. These results broadly suggest
mycobacterial involvement in CD acquisition [34].
It should be noted that, despite the similarities of CD and UC in their
symptoms, UC-infected patients rarely test positive for MAP, showing that the
presence of MAP is specific to CD. A 2001 review by El-Zaatari et al. compiled
recent research utilizing various detection methods including: direct culturing
from diseased tissue, DNA hybridization, serological methods, and in situ
hybridization[34]. All were able to detect MAP in CD patients with MAP
9

prevalence values ranging from 40% to 90% of CD patients tested. On the
contrary, UC patients rarely exhibited MAP presence with prevalence values
ranging around 0% with only one DNA-DNA hybridization test result having an
outlier 33% prevalence. Non-IBD negative controls also tended towards zero
prevalence rate with, again, the exception of the hybridization test which revealed
a 17% prevalence of MAP [35]. Still, there exists the possibility that CD-infected
tissues somehow provide a more lucrative environment for MAP to establish
itself. Therefore, mere presence of MAP within CD patients is not enough to
prove MAP causation. This may be supported by the very mixed success rates of
using anti-mycobacterial treatments reviewed by Chamberlain et al. [28].
Symptomatic Similarities Between CD and JD
MAP is well-known as the causative agent of an intestinal chronic disease
in ruminant animals, called Johne’s disease (JD), and symptomatic similarities
between CD and JD have supported the hypothesis of an etiological role of MAP
in CD. Both diseases can result in a constant diarrhea and, in severe cases, can
lead to lethal blood loss or anemia. There are important similarities when one
observes the inflamed tissue taken from diseased ruminants and humans as well.
Granulomas are the main common feature to both tissue types. CD- and JDinfected tissues have goblet cells that are responsible for proper mucous secretion
along infected areas [7]. Transmural inflammation, while rare in JD, is also a
common feature of CD tissue samples [5]. In a 2004 review, Chacon et al.
highlights the similarities in diseased tissues of UC, CD, JD seen in Figure 3 [5].
However, there are some differences in symptoms of CD and JD as well. JDinfected tissues usually inflame the lamina propria while this is rarely seen in CD
patients [5]. Another important distinction is the lack of fistulas, fissures, and
pseudopolyps in JD-diseased tissue – these features are common in CD tissues.
Since MAP has been studied intensively as a candidate causative
agent of CD, details of MAP biology and MAP infection in animals, JD,
are described below. A complete understanding of the biology of the
disease – and how it may make it through the food chain to our
refrigerators – helps one to understand the significance of this bacteria as a
zoonotical suspect.
MAP General Characteristics
MAP belongs to the genus Mycobacterium, which encompasses nearly
100 species [5]. MAP bacilli resemble 1-2 micrometer long, plump rods when
viewed microscopically [36]. Taxonomically, the Mycobacterium genus is most
closely related to the genera Corynebacterium, Nocardia, Rhodococcus, and
Streptomyces. Microbiologists often characterize bacteria by the guaninecytosine makeup within the microbe’s DNA; often called he G-C percentage.
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Figure 3: Histology comparison between normal, UC, CD, and
JD tissues (from Chacon et al [5])

t MAP DNA has a characteristic G-C content of approximately 69% [37].
A defining trait of all Mycobacteria is their propensity for acid-fast
staining. Members of the Mycobacterium genus contain high concentrations of
mycolic acid in their cell wall. This component binds to the basic fuchsin dye
used in the first step of the Ziehl-Neelsen Acid-fast staining procedure. It does so
when the carboxylic acid portion of the mycolic acid forms an ionic bond to one
of the amine groups of the fuchsin [38]. This cell wall component is impermeable
to the acid-alcohols used for decoloration. The mycolic acid is also covalently
bound to the peptidoglycan of the cell wall. The cell wall of mycobacteria is
covered further by capsular structure (also called outer layer) composed primarily
of carbohydrates and proteins. Further, the bacteria tend to produce a large
amount of extracellular matrix which can be seen in a recent scanning electron
microscopy image (Figure 4) taken by our laboratory in April of 2007.
Extracellular pili resembeling those in the figure have recently been described by
Alteri et al. in MAP’s close relative M. tuberculosis [39]. Further, the
investigators revealed that MAP was found to carry the same gene responsible for
pili in M. tuberculosis.
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Figure 4: MAP image revealing extracellular material

Amongst the Mycobacterium, there are two large groups; fast-growing and
slow-growing. Those in the latter group comprise most of the known pathogenic
strains of the Mycobacterium genus, including MAP, along with its infamous
pathogenic relatives M. tuberculosis and M. leprea [40]. These can be easily
distinguished from fast-growers because slow growers only contain one set of
rRNA genes, whereas fast growers contain two sets [41]. Susceptible hosts vary
considerably: MAA causes tuberculosis in birds, and opportunistic infections in
immunocompromised humans. Yet, MAA does not cause disease in cattle or
other ruminants. [42]
MAP is one of three subspecies belonging to the mycobacterium species
M. avium [41] – the other two being Mycobacterium avium subsp. avium (MAA)
and Mycobacterium avium subsp. silvaticum. Of the three, MAP is the slowest
growing with a generation time that can exceed 20 hours [5]. A recent genomic
analysis between M. avium subsp. avium and MAP revealed greater than 97%
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genomic similarity between the large genomic sequences chosen for the
comparison [43]. Analysis of the dnaJ gene, a highly conserved heat shock
protein used for phylogenetic analysis, revealed a 99% homology between the
same two subspecies [44]. While the genetic and physiological make-up of these
two seem to be related, the diseases and
Recently, Li et al. used shotgun sequencing to determine that the entire
genome of a laboratory strain of MAP, K10 was about 4.83 kbp long [37]. M.
avium subsp. avium is substantially larger, with a genomic size of 5.48 kbp [5].
The homology is such that the two subspecies probably differ by fewer than 75
genes. Lastly, many other mycobacterial species, including MAP’s closest
relative MAA, have plasmid DNA in their genomic arsenal. No such native
plasmids have been found in MAP [45].
Two other key features distinguish MAP from related bacteria. These are
mycobactin J-dependence and the presence of a specific genetic insertion
sequences [45]. Unlike all other known mycobacterial species MAP is a
mycobactin auxotroph. Mycobactins (lipid soluble iron chelators), along with the
exochelins (water soluble iron chelators) are responsible for iron scavenging to
ensure survival in iron-depleted environments. Mycobactins contain a
phenyloxazolidine ring while exochelins do not [46]. In MAP and other
mycobacterial species, both mycobactins and exochelins are necessary. Since
MAP lacks mycobactin J, it must utilize foreign, extracellular mycobactin J in
iron-starved conditions. This is why the bacterium was so difficult to culture.
Twort was able to get around this because the M. phlei was providing the
mycobactin J for MAP.
A distinguishing feature of MAP is the presence of the insertion sequence
IS900 [45]. This is a small, highly motile bit of genomic material which contains
transposition-related genes. Specifically, IS900 is a member of the IS110 family
of insertion sequences [45]. It therefore lacks both the terminal inverted repeats
and direct repeats expected in most transposable DNA. Typically, 17-20 copies
of these insertional sequences are found in MAP. Other mycobacteria have
similar, but distinct, insertion sequences. As expected, MAA has the insertional
sequence most closely resembling IS900. Its version, IS1626, shares 82%
homology with IS900 and is also in the IS110 family. Yet we expect to find
IS1626 in copies of three when probing MAA cells [45].
Even within the MAP subspecies, significant variation is evident. This
seems to be related to where the MAP subspecies is isolated from. Two major
subspecies strain include the cattle (c strain) and the sheep (s strain) strains. In
reference to the only fully sequenced C strain (K10), a DNA microarray
hybridization revealed significant deletions an S strain. These deletions totaled
approximately 30,000 base pairs which are about 0.6% of the genomic size of the
reference C strain. However, this test is only unidirectional and a second
hybridization with a reference S strain must be conducted to ensure the deletions
exist [47]. Lastly, it is important to note that there are subtle key differences
within the IS900 sequence of MAP which allow us to determine our strain type
[48]. We include further discussion of IS900 in the diagnostic methods section.
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Role of MAP in Animal Disease
Johne’s Disease
Johne’s Disease (JD), often referred to as ‘paratuberculosis’, caused by
MAP, is a chronic, often fatal enteric disease which mostly infects ruminant
animals. In particular, it affects cattle and sheep -- the important economic
cornerstones of many agricultural economies. It is prevalent on every continent
except Antarctica; in the United States prevalences reach as high as 85% on some
farms [49]. Various characteristics of this microbe have made the eradication of
Johne’s disease a very difficult prospect. The economic implications of Johne’s
disease can be quite severe and thus, a great deal of research has gone into JD.
For example, it is now known that non-ruminants also harbor the acid-fast
bacterium: in 1977, Matthews and Sargent isolated MAP from a brown hare [50].
Such a vast host range represents an extremely tough obstacle for designing
effective management techniques.
In general, animals are most susceptible to infection during the first few
months of life [51]. While initial exposure occurs early, classical clinical
conditions may take years to develop. Transmission is believed to be primarily
linked to oral ingestion of MAP-laden material. Experimental infection models
with adults have proven that disease resistance is acquired with age [8]. JD can
be spread via direct and indirect contacts mechanisms. The most common means
for direct transmission is through an infected mother’s milk or colostrum (first
milk after calf delivery) [51].
Indirect transmission occurs most commonly via MAP-contaminated food
or water sources. Teats contaminated by fecal material can also cause oral-fecal
transmission [51]. The minimal infective dose of MAP appears to be 103 bacilli
[52]. Infected animals with clinical symptoms shed 106 to 108 MAP per gram of
fecal material [52]. Thus, just a small amount of fecal contamination will go a
long way in spreading disease. To make matters worse, the onset of fecal
shedding of MAP by infected cattle is nearly impossible to predict.
Once infection is initiated, JD is mostly undetectable for the first couple
years. Thus, the disease spends much of its time in a subclinical phase [51]. Only
5-10% of the subclinically infected animals will progress to more overt
symptoms[51]. A late subclinical phase is marked by heavy bacterial shedding
with no overt symptoms prevalent [53]. Clinically infected animals shed high
numbers of bacteria in their feces, rapidly lose weight, and exhibit low milk
production. Symptomatic animals will eventually die due to malnutrition.
MAP’s ubiquitous distribution in the environment makes it impractical to
eliminate the bacteria from a suspected farm. Once infected, chemotherapeutical
agents may be employed which will may reduce the severity of disease and in turn
increase survival time. However, no chemotherapeutic agent has been found that
will completely relieve all symptoms and guarantee relapse prevention. Vaccines
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represent a second form of protection. Yet, there have been only a few successful
demonstrations of both live and killed bacteria vaccinations [54].

Survival of MAP in environment and milk
As mentioned earlier, MAP bacilli are surrounded by multiple layers,
including cell membrane, cell wall, capsular structure and extracellular matrix,
and are known to be extremely resistant to various chemical and physical
treatments. Consequently, MAP can survive in environments (e.g. soil and water)
and food matrices (e.g. milk) for a relatively long term with maintaining their
infectivity. Since the majority of MAP transmission occurs through the oral
route, contaminated materials are likely to cause the spread of MAP infections in
animals and possibly in humans. If MAP is a causative agent or deteriorating
factor of CD, survival of MAP in drinking water and milk will be a food safety
concern especially in countries where JD prevalence is known to be high.
MAP’s Physical Resilience In Vitro
MAP is an extremely durable organism. In the lab, it is able to resist high
temperatures better than any of its closely related family members including M.
avium subsp. avium, M. phlei, M. scrofulaceum, and M. xenopi. Normal doses of
UV light are adequately capable of killing the organism, yet the organism is
slightly more capable of surviving sunlight than M. bovis. Slight differences in
overall pH in the 5-8 range have no effect on MAP’s survival. Like MAA,
chlorine has been showed to have a less pronounced effect on MAP survivability
when compared to most other bacteria.
MAP’s Environmental Resilience
With such an enduring nature under laboratory conditions it is hardly
surprising that this mycobacterium has also proven to be hearty in various
environmental sampling experiments. The bacterium remains extremely viable
under various environmental conditions. For instance it has been cultured after
163 days in river water, 270 days in pond water, and 11 months in cattle feces
[55]. Low temperatures can also be tolerated, as it has been cultured @ 14
degrees Celsius for at least a year [55].
MAP’s Survival of Pasteurization Process
If MAP does cause a zoonotic disease in humans, its survival within
commercially available dairy products would represent a very serious risk. The
mycobacterium has been isolated from both pasteurized and unpasteurized milk of
infected dairy cattle. Pasteurization is a process which was designed to eliminate
possible bacteria (namely Mycobacterium bovis the etiological agent of
tuberculosis) or other biologically active entities that can be found in collected
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milk. The mycobacterium is found in milk by either direct secretion from the
udder or a contamination of the udder by MAP-laden fecal matter. While milk
shedding is less prevalent than fecal shedding, it has been shown that about 30%
of heavily infected animals will shed the bacteria in their milk[55]. While most
studies have found low MAP counts from milk, shortcomings in current
methodology prevent us from knowing the true viable MAP count in milk. The
processes used to rid the milk of faster growing organisms, are also harmful for
MAP. Secondly, fecal-contaminated milk enumeration methods have yet to be
undertaken [36].
Different methods exist for milk pasteurization. Mainly these consist of
holder pasteurization and high temperature, short time pasteurization. Holder
pasteurization entails heating the milk to 63 degrees Celsius for an extended 30minute period. High temperature, short time pasteurization involves a higher
temperature of 72 degrees Celsius for just 15 seconds. Several studies have been
conducted using experimentally inoculated milk samples which were
subsequently pasteurized using both methods. Both methods were proven unable
to completely rid the milk of viable MAP. In addition, minimal starting
concentrations of MAP in the milk are important if we are to seriously consider
the possibility of MAP transmission through commercially available milk. It has
been shown that if milk is present at levels as low as 100 cuff/ml (colony-forming
units per milliliter) some MAP survival is plausible under high-temperature,
short-time pasteurization [36]. Thus, cows with at least this concentration of
viable MAP in their milk could be considered a public health risk; at least until
the Johne’s disease/Crohn’s disease connection has been convincingly invalidated
[55].

MAP Detection/Diagnosis
Preamble
Most of the information garnered thus far on MAP detection has been
acquired using animals affected with JD. Since this is the only disease MAP has
been proven to cause, this is hardly surprising. Thus, this section focuses on
MAP detection techniques that have been developed for JD, but which might also
allow us to look for MAP in CD patients to help evaluate the putative connection
between the two.
Detecting MAP in an Infected Host
The jury is still out as to which diagnostic method should be utilized in
accurately assessing one’s MAP infection status. Since the disease has only been
proven to cause Johne’s disease, most studies concentrating on finding direct or
indirect evidence of disease have concentrated on its known animal hosts.
Disagreement between labs using the same methods are common in the literature.
There are many reasons why this may be true, including strain differences, the
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slow-growth of MAP, and the heartiness of the bacteria to name a few. Two
important facets of any diagnostic method are its intrinsic sensitivity and
specificity values. These statistical terms are straightforward in their meanings.
Sensitivity refers to a tests ability to detect all true positives. Its value is only
lowered by false-negatives. Specificity refers to a tests ability to accurately assess
the true negatives for a disease. High combined specificities and sensitivities
indicate that the test is both able to detect disease and differentiate the healthy
from the infected. Early detection of Johne’s via serological or non-serological
methods remains a difficult task. Thus while high specificities may be possible
due to the low prevalence of false-positives, true negatives may be much less
prominent. This is because an infected animal may take months to years to
progress to a disease state where detection is even possible due to the pathology
of MAP. The following discussion represents a synthesis of the newest research
conducted and tries to gather some of the general sensitivity and specificity trends
of each diagnostic method.
Fecal Culturing
Though there may be some who disagree, most researchers familiar with
the diagnostic aspects of Johne’s disease would consider the fecal culture test the
gold standard by which all other tests are usually compared against. Though it
has taken many years since fecal culturing began, today we are able to detect the
presence of the bacteria both earlier and at lower initial prevalence. However,
many questions still exist as to whether or not fecal culturing should be assumed
to be the gold standard for infection status. The bacteria can be extremely
difficult to free from the fecal matter, and for this reason many low-shedding
hosts may be misdiagnosed as being fecal culture negative. In addition, since the
mycobacteria are often consumed via contaminated feed or milk, there is a
possibility that some fecal positive cultures are the result of these bacteria simply
being processed and excreted with the ingested material.
Thus, there is the risk that the bacteria could be detected without ever
establishing an infection. Cultures testing positive in this manner are said to be
‘pass-through’ positives [56]. Other problems with fecal culturing are the
considerable efforts which must be expended to determine a given samples
disease status. The filtration and decontamination stages can be completed in 3
days by the Whitlock method [57], however even with sophisticated growth
detectors, some cultures may take up to 60 days until microbial growth becomes
evident [57]. With such prolonged incubation times, laboratory costs can be very
high.
Despite these drawbacks, fecal culturing still represents one of the only
direct methods to detect MAP. Consequently, many still rely upon fecal culturing
to obtain a cow or herd’s disease status when looking for Johne’s diseased
animals. While fecal culturing has become the standard for detecting MAP within
the Johne’s disease animal hosts, the method has yet to be found useful in any
Crohn’s disease studies. However, as previously mentioned, there have been
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several accounts of culturing MAP from various tissues and non-fecal fluids of
CD subjects [1, 31].
Serological Methods: An Introduction
Blood can be physically separated into different components of which the
main constituents are plasma (the liquid portion) and red blood cells (the solid
portion). These can be obtained by simple centrifugation. Plasma has many
proteins associated with clotting called clotting factors which can be removed
immobilized with special coagulants. Once these clotting factors have been
removed serum is what remains. The sera contains antibodies and complement
proteins. In addition, other proteins exist within the serum that act as chemical
signalers (cytokines) for different components of the innate and adaptive immune
responses.
Thus, it is clear that serum can provide us with a wealth of information
about a particular organism’s immune responses. Because we cannot readily
detect the actual invasive organisms within the serum of an animal, serological
testing remains an indirect, but very effective detection method. Many different
serological testing techniques have been developed to detect different aspects of
the host organisms’ immune system.
Humoral Immune Responses
The humoral immune response is directed by a strong TH 2 response. That
is, type 2 helper T-cells activated by the antigens direct B lymphocytes to mature
into antibody secreting plasma B cells. The antigen-specific antibodies may then
bind to the surface antigen of free bacteria and mark the bacteria for eventual
destruction via one of a number of available pathways including opsonization and
complement killing. Antibodies to a common antigen may exist in a variety of
isotypes. A variety of isotypes exist to allow the antibodies to capture antigen in
multiple ways. These may be produced by the same TH 2-activated B lymphocyte
[38]. IgG is structurally very simple and is generally the most prevalent
antibody circulating in tissue and blood of animals [58].
For years, the humoral immune response was thought to take a significant
amount of time to develop in a typical paratuberculosis infection [59]. Thus it
was considered by many to be an immune response dominating the later, clinical
stages of MAP infection. One major reason for this is that the enzyme-linked
immunosorbant assays (ELISAs) often used to detect antibodies to MAP antigens
are mostly seropositive after the animal has been shown to be shedding bacteria
via fecal culturing. Yet, recent work by Koets et al. challenges many of these
assumptions [60]. An advanced knowledge of the immunology concerning MAP
infection will likely improve humoral immunity detection methods. We will now
discuss some of the common methods used to detect MAP-targeting antibodies.
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AGID and CF Tests
There are agar gel immunodiffusion (AGID) and complement fixation
(CF) tests for the presence of antibody to MAP antigens. Developed prior to the
more sophisticated ELISA, these two assays offer an easy, quick visual
affirmation of antibody presence. Both tests are fairly specific, but lack the
sensitivity achieved by most ELISAs in cattle, goats, and sheep [61-63].
AGID tests are extremely simple as they require only MAP antigen, the
serum to be tested, and a known positive control. Test results are available in two
days [64]. The three constituents are placed equidistant from each other and
injected into an agar gel. If the antibodies to the antigen are present in the serum,
the two will bind to form a precipitant. A precipitant describes an insoluble
complex formed from a soluble antigen and antibody [38]. This line should be
compared to precipitant line from the positive control. The Johne’s Information
Center recommends that this test only be conducted on animals which have been
clinically diagnosed due to their malnourished appearance or constant diarrhea
[64]. There are no records of AGID testing with CD subjects.
The CF test utilizes an indirect indicator system to portray antibody
presence. The presence of antigen binding antibody is indicated by adding
complement proteins. Complement proteins exist as a part of our immune
response to trigger a cascading effect of activating proteins which lead to effective
clearing of pathogenic cells by creating holes in their cell membranes [65].
Complement proteins can be activated by a variety of different pathways.
The classical pathway exists as an antibody-activated pathway [38]. The
test works in the following manner; if the antibody is present within the serum, it
will bind both the antigen and activate or “fix” the complement protein. A second
indicatory antibody is added which leads to sheep red blood cell lysis upon
complement binding. If all of the complement is already bound to the antibodies
against MAP antigen, there will be a drop off in complement available to bind the
anti-sheep RBC antibody. Therefore, when we add sheep red blood cells
hemolysis will occur to a lesser degree and the lawn of red blood cells will remain
intact. This would appear in the test well as a solid red lawn.
However, if there is no antibody binding to MAP antigen, the inactivated
complement proteins will be more freely available to bind to the anti-sheep RBC
antibodies. This will activate the classical complement system to eventually lead
to hemolysis. This would appear as a white or pink lawn in the test. There have
been no similar CF tests done on CD patients.
ELISA
The enzyme-linked immunosorbant assay or ELISA has become the
preferred method of antibody detection since its development by Yokomizo et al.
in 1983 [66]. The ELISA is the preferred immunoglobulin detection method
because it requires the least amount of antibody required to give a positive
reaction [38]. It is also relatively cheap, and easier to standardize making
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duplication easier [64]. Lastly, it is important to note that specificity of the
ELISA significantly improved when M. phlei-absorbed ELISAs were introduced
to reduce non-specific antibody binding and hence, false positives [67].
The ELISA for JD works by having some MAP antigens attached the
wells of a ELISA plate [38]. Serum at a specific dilution is then added to the
wells and allowed proper incubation time for the reaction between antigen and
antibody to occur. The wells are then washed to remove any materials that did
not bind to the antigen. A secondary enzyme-conjugated antibody specific for the
animal and isotype of your targeted antibody is then pipetted into the wells. After
a second incubation the substrate for the enzyme is added to the wells. If there is
any antibody present for the targeted antigen, the secondary antibody with its
conjugated enzyme will also be present and reacts with the substrate producing a
coloration of the solution in the well. The coloration of each individual well is
directly proportional to the amount of antibody present. These are read on an
ELISA plate reader which quantifies the optical density or OD [38].
Like IFN-γ, a number of different antigens have been used with ELISAs.
This includes LAM proteins, heat-shock proteins, whole-cell MAP, ethanol
extracted antigen, antigen 85, antigen 35, and antigens removed by whole-cell
sonication techniques [60, 68-71]. In addition, different methods for antibody
detection have been tried. This has been mostly dominated by the extremely
popular ELISA. Thus far, very few ELISAs have been able to separate the
populations with much effectiveness (See table 1-1). Yet, there is hope with the
ethanol-ELISA, the formaldehyde-treated ELISA, and the p35 ELISA having
sensitivities in the 85-100% range [69-71]. It must be noted, however, that
whilst the p35 ELISA has shown a high sensitivity, it has a lower specificity
(86.4%) than either of the other two aforementioned ELISAs which approach
100% [69-71].
ELISAs have been the most popular method for testing CD patients for
MAP-directed antibody production. Kreuzpaintner et al. used their own ELISA
that utilized 45/48 doublet antigens shared between M. tuberculosis and MAP
[72]. Bernstein et al. used a commercial ELISA to test seroreactivity between CD
and HC groups [33].

Using Flow Cytometry to Detect Bacteria
An Introduction to Flow Cytometry
Over the years, flow cytometry has proved to be an extremely useful tool
in the medical and scientific community. It has served as an extremely potent
investigative tool for researchers wishing to address a wide array of biological
questions. These may include the monitoring of foreign or self-antigens,
antibodies, chemokines, and key immunological markers. Its applicability stems
from the extreme sensitivity and specificity one is able to achieve with flow
cytometry.
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By its name the machine may seem deceptively simple. Cytometry refers
to the equipment for the characterization and measurement of cells and cellular
constituents. The ‘flow’ portion refers to how this cytometry is accomplished; by
flowing a liquid stream containing the target of interest through an array of
detectors. This flow procedure allows for the subjects of interest to be lined up in
the stream. Once these targets are lined up, they pass through a laser beam and
florescence emitted from or light scattered by the targets be captured by a
detector. The flow rate through the stream is controlled and constant, thus only
the particles size affects how long the laser is kept from hitting its detector.
Intensity of the fluorescent and light is converted into voltage, amplified and
digitally recorded.
Thus flow cytometry is both quantitative (frequency) and qualitative
(size). This beam breakage between a source and a detector is called “forward
scatter”. In addition, secondary detectors will be set up to observe where the
beams which encounter the particle are deflected. This deflection is called “side
scatter” and is observed by side scatter detectors (usually oriented about 90
degrees to the laser). While forward scatter mostly measures cell surface area or
general size, side scatter can give good approximations of how a cell is deflecting
light. This deflection pattern is a qualitative property that details cell topography
and can even give hints as to intra-cellular structure. A cell with a rough surface
is not going to deflect light in as ordered of a manner as a nearly perfectly smooth
sphere bead. It is important to note that both side-scatter and forward scatter can
be utilized to estimate particle size [73] .
In both cases, computers allow these measurements to be recorded and as
many as 3 x 105 measurements can be made in a single minute [73]. In addition
to size and frequency recordings, most flow cytometers will have the ability to
excite a fluorescent marker that may be attached to the target of interest.
Secondary detectors will detect this fluorescence as it occurs and store it
alongside the particle size information. In this manner, the flow can be extremely
specific. Fluorescent monoclonal antibodies can be made which only bind to very
specific epitopes. If they are not bound, no fluorescence can occur and although a
false positive may have a similar sized particle, it is nearly impossible that it will
also contain the same epitope. Another crucial aspect of modern day flow
cytometry is the ability to make several simultaneous readings upon a single cell.
For instance, if one wants to measure the expression of antigens A, B, C, D within
a given population of cells, it would be possible to measure these for both the
individual cells and within the population as a whole, as well. A diagram of a
typical flow cytometer is outlined in Figure 5.
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Figure 5: General schematic of flow cytometer courtesy of
University of Arizona Department of Microbiology
http://microvet.arizona.edu/courses/mic419/ToolBox/f2fasc.gif
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A Brief History of FCM Development Towards Studying
Microbes:
Though it has its conceptual origins under Moldovan as early as the 1934,
it was not until the 1950’s -- with the advent of a detector developed by Coulter
that could differentiate cell volumes [73] - that flow cytometry (FC) began to
make significant progress. These early flow cytometers were equipped with
“Coulter Counters” that used the differences in electrical signal absorption from
their media to determine approximate volumes [74]. Optical means of cell
volume differentiation later replaced the Coulter Counters due to their superiority
in many different aspects of cell volume differentiation. Cell sorters were a
second important milestone in the evolution of the flow cytometer. This feat was
achieved by Fulwyler who was able to successfully sort human and mouse red
blood cells based on differences in their total cell volume [75]. This apparatus
would allow the investigator to single out only the cells of interest to be studied
and eliminated an enormous amount of possible background noise.
Improvements in optical technologies and fluorescent markers allowed
researchers to begin investigating the microbial world using flow cytometry
around the1970’s [74]. In an important early experiment, Hutter and Eipel were
able to observe previously undetectable microbial entities. Various measurement
parameters including, protein content, DNA content, and chlorophyll content were
measured from a diverse group of microorganisms that included some yeasts (S.
cerevisiae) , a prokaryote (E. coli), and some filamentous fungi [76]. This work
was conducted using a flow cytometer developed primarily for working with
larger, mammalian cells. A necessary final step had to be taken in order for flow
cytometry to be of use for microbiologists: bacteria and similarly small particles
needed to be studied using instruments that had a high signal to noise ratio. This
meant eliminating background noise.
In 1979, Steen and Lindmo addressed this issue by redesigning the chamber
through which the fluid and laser interact [77]. They aimed for the fluid to flow
over a glass cover slip in an ordered manner which created a laminar flow [77].
This cut down on background noise and allowed for a high enough sensitivity to
detect smaller prokaryotes. There was a catch, however, because these flow
cytometers utilized arc lamps instead of lasers. With arc lamp flow cytometers,
multi-parameter flow cytometry of more than two fluorescent parameters is not
possible [74]. Cell sorting is also not an option with arc lamp models. With time,
further improvements in laser and computer technology allowed the laser-based
flow cytometers to become sensitive enough to detect the smallest bacteria. Even
smaller biological materials, such as DNA, can now be observed. Armed with
these more precise instruments, research on bacteria using FCM has become
much more prevalent as evidenced in Figure 6 by Davey et al. in their review of
flow cytometry [74].
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Figure 6: Graph displaying increasing flow cytometry
papers concerning microbes during the period from 19801996. Davey et al. did a database search on two criteria: for
any paper concerning flow cytometry (open circles) and for
any papers containing both the words ‘flow cytometry’ and
‘bacteria’ (solid circles). The percentage of flow cytometry
papers dealing with bacteria were then mapped as a
percentage of the total papers dealing with flow cytometry in
general (open triangles) [74].
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Fluorescent Staining in Flow Cytometry
When an atom absorbs light energy, its electrons enter an excited state in
which they may jump to a higher energy shell level. When they return from this
level to the normal, ground state a photon with a characteristic energy can be
emitted. This everyday phenomenon is termed “fluorescence” and it can be a
valuable tool when optimized in flow cytometry. Since fluorescence is always of
lower energy than the light energy that initiated the phenomenon, the emitted
fluorescent light may be detected and quantified [74]. Different fluorescent dyes
have characteristic extinction coefficients which dictate at what wavelengths of
light a particular dye will absorb the maximum amount of light. In addition,
different fluorescent dyes emit at different wavelengths. This makes possible
multiparameter techniques not only using flow cytometry but also simple
fluorescent dye microscopy.
Fluorescent staining in flow cytometry allows us some very distinct
experimental advantages [73]. First, a fluorescent emission is directly
proportional to the fluorescently-tagged biological materials. Secondly, very low
concentrations of any fluorescent dye may be detected, due to the possibility of
multiple fluorescent emissions per passage through the beam. This provides a
general amplification of the signal and leads to greater overall sensitivity. Lastly,
non-fluorescent compounds can be altered by enzymes to allow for fluorescence.
This allows us to saturate a sample and only detect those which have the
appropriate enzymes.
Ideal dyes for flow cytometry have extinction coefficients which are
highest at the corresponding wavelength energies of the lasers of the flow
cytometer being used. Other crucial properties include how many times a
molecule can be excited before it breaks down, what is the maximum energy a
dye can withstand before it breaks down, the duration of fluorescence, and how
sensitive it may be to its chemical environment [74].
Fluorescin isothiocyanate (FITC) is one of the most widely used
fluorescent dyes in all of flow cytometry. FITC has its maximum absorption
wavelength at 490 nm. This is ideal because most flow cytometers use a argon
laser which has a blackbody radiation curve peaking at 488nm [74]. FITC emits
a photon with a characteristic peak at 520 nm and these photons are generally
detected at sensors adjacent to the side-scattering detectors. FITC also can exert
multiple signals per molecule because it exerts its photon over a very short period
of time of 4 nanoseconds [78]. Since the typical sample passing through a flow
chamber contacts the laser for 10 to 100 microseconds, the detector will observe
more than one signal from a tagged item and thus will be more sensitive to even
trace amounts of FITC-tagged material. Lastly, FITC also has a high quantum
yield at biological pHs of 8 making detection optimal for typical biological assays
[74].
FITC can either be used in two important, but distinct manners. First,
researchers may use FITC to bind to all available proteins in a given sample [79].
This allows access to a number of data collecting possibilities including the ability
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to distinguish cell cycle status, differentiate different cell types based on overall
protein expression, or any other investigation when the amount of protein per
constituent may be of interest. Secondly, more specific assays may be done by
conjugating FITC with antibodies to bind only one particular antigen type [73].
Once these antibodies bind their target, the attached FITC will fluoresce when the
complex passes through the argon laser. Similarly, FITC secondary antibodies
which bind to species-specific antibodies are commonly used.
Fluorescent-based FCM Method by Dietrich et al.
Humoral responses to bacteria have been measured in a number of
different ways, as discussed previously. However, in 1991 Dietrich et al. outlined
a method for detecting host immune responses to whole-cell bacteria using flow
cytometry [80]. In this original study, the authors used a secondary antibody
conjugated with FITC which targeted the F’ab regions of the bovine IgG
antibody. The study focused on a group of 18 cattle which were challenged with
live B. abortus. They sampled blood from the cattle at prechallenge, 1, 2, and 4
weeks post-inoculation. In the initial step of the assay, they incubated bovine
serum with the B. abortus which was fresh from a culture. After the incubation,
nonspecific antibody binding the bacteria was prohibited by washing twice with
PBS. A second incubation with the FITC conjugated-anti bovine secondary
antibody was performed. Washes were performed after an incubation period and
the bovine antibody binding to B. abortus was assessed using flow cytometry.
The results of the study proved very promising:antibody titer increased from a
near zero level as expected as the weeks progressed and the cattle’s immune
systems began producing immunoglobulins to the challenge bacteria. The study
ended with exciting results as the authors proclaimed,
“In summary, we have developed a fluorescence based flow cytometric assay to measure
antibody binding to intact bacteria using blood samples as the source of antibodies. The
assay was as reproducible as the standard EIA (ELISA-immunoassay), it was easier to
run and it produced data in a format that was more applicable to our research needs. We
are using this assay to measure specific antibodies in bovine plasma samples to B.
abortus but the assay could be suited to the measurement of antibody to binding any
bacteria.”

Developing a FCM Method for MAP antibodies
In 2005 our lab developed a similar flow method to detect antibody
binding to MAP in sera of cattle on JD+/- dairy herds [2]. Like the Johne’s
ELISA, the Flow Cytometry Method (FCM) also uses a secondary antibody as an
indicator of the presence of antibodies against MAP. In principle, the idea is to
incubate serum with whole-cell MAP to allow antibody to bind to the surface of
bacilli. Washes remove unbound materials and the bound host antibodies are then
tagged using FITC-labeled secondary antibodies that are specific for bovine
antibody. The general idea is captured in Figure 7. Here we have a complex
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Figure 7: Schematic of the antibody binding
complex that is detected by FCM
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composed of antigen, bound primary antibody from the serum, and bound labeled
secondary antibody that is labeled with FITC for detection.
The complex is then run through the flow cytometer to detect antibody
binding by immunofluorescence. When tested with other related mycobacterium,
this study proved the assay to be specific for MAP antibodies. The lab used 21
serum samples from cows which had produced 2 or more positive fecal samples
as the positive controls. Serum samples from 30 cows which had been testing
serum negative by ELISA for 20 years were used as the negative control and gave
both the diagnostic specificity and cut-off value. The mean fluorescence of this
group was determined and the cut-off was set three standard deviations above
mean negative fluorescence value. Using this method, the assays’ sensitivity was
estimated to be 95.2% with a specificity of 96.7%. This differentiation is shown
in the S/P dot plot depicted in Figure 8.

Figure 8: Differentiation of JD negative (1)
and JD positive (2) cattle sera, based on
FCM-derived S/P values (from Eda et al [2])
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CHAPTER III: Materials and Methods
Serum Populations
Serum samples from a total of 74 individuals were tested using the FCM ;
37 were from known CD patients (the CD group - all volunteers) and 37 from
healthy controls (the HC group). All 37 CD patients came from our collaboration
with M.D. of Gastroenterology, Dr. Anderson. Dr. Anderson is assistant
professor and Chief of the Gastroenterology Division at UT Medical Center. In
April 2005 his patients were sent a letter asking them to participate in our study.
The packages included a cover letter (Figure 9) and an agreement to the terms of
the study (Figure 10). The patients were directed to come to UT Medical center
and have blood collected at their convenience. Patients diagnosed CD by
Dr. Anderson or any previous M.D. were considered to be truly positive for the
assay purposes. Any donated blood was collected by trained phlebotomist
personnel and placed in BD Vacutainer © (BD bioscience, Franklin, New Jersey)
serum collecting tubes. The tubes were usually picked up and transported back to
our lab for proper storage at -20ºC. The samples were documented with names,
ages, and gender.
Healthy controls (HC) were obtained from three independent companies.
Bioreclamation Inc provided us with 20 samples which were donated by those
claiming to be CD-negative by questionnaire (Bioreclamation Inc. New York,
NY). Since CD-positive blood is more valuable and therefore the donor can
receive more compensation, the questionnaire is rarely falsified when it comes to
disease status. Seventeen other CD-negative samples came from Profile
Diagnostics Inc. and were guaranteed to be CD-negative by questionnaire, as well
(Profile Diagnostics Inc. Sherman Oaks, CA).
Once in the lab, aliquots of sera were made by first spinning down the BD
vacutainer tubes and collecting the remaining supernatant. Aliquots were
subdivided into 2.5 ml master tubes, and smaller 600 µL tubes. This was done to
assure we had appropriate back-ups in case that a serum is contaminated with
other sample or that antibodies in serum are inactivated by multiple freeze-thaw
processes. The larger volume, stocking tubes were kept in freezer at -80ºC. The
smaller tubes to be used directly in the experiments were kept at -20ºC for easier
access and shorter thawing periods. All CD-negative and CD-positive sera were
relabeled with a numbering system for ease of experimentation and labeling
purposes.
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Dear Crohn’s Patient,
I would like to invite you to participate in a study that is being conducted by Dr. CA
Speer’s Laboratory at the University of Tennessee, Agriculture Campus. Your
participation requires a one time blood draw of 10-20 mls (a little more than a
tablespoon) and a disclosure of your age and gender. The blood will be drawn at UT
medical center’s phlebotomy laboratory and the procedure should take less than 15
minutes. There will be no cost to you or your insurance company for the blood draw.
As you are aware Crohn’s disease (CD) is currently diagnosed by a combination of
tests, including blood/stool test, X-ray examination, colonoscopy and biopsy. Since
some of these tests are difficult, invasive and hard to interpret, there is a need for a
simple and less-invasive test for the disease. It has been shown by some investigators
that most CD patients have serum antibodies against a bacterium, called
Mycobacterium paratuberculosis, which may be involved in CD. Dr. Speer’s Lab has
developed a method to detect such antibodies with high sensitivity and specificity, and
the method requires only a small amount of blood from patients with CD. Further efforts
on the development of a diagnostic test for CD based on the Speer Lab method would
benefit CD patients by providing more accurate diagnosis and by reducing risk, cost,
and time required for diagnosis.
Mycobacterium paratuberculosis (MP) causes a disease similar to Crohn’s disease in
cattle and other animals called Johne’s disease. MP involvement in CD has also been
indicated in a number of scientific studies but to date no conclusive evidence has been
found. However, recent studies showed that antibiotic treatments that are effective
against MP resulted in long-term remission of CD, supporting the hypothesis that CD
might be caused by mycobacteria. The test for MP developed in Dr. Speer’s Lab is far
more sensitive and specific for MP bacteria than anything that has been provided
previously. If these studies help prove that MP is involved in CD it may lead to new
therapies for Crohn’s disease. If you have questions about the Informed Consent
Form or if you would like scientific literature or more information on MP please
contact Cathy Scott at 865-974-0465 or mcscott@utk.edu.
If you are willing to participate in the study please fill out, sign and take the
enclosed Informed Consent and Dynacare forms to the University of Tennessee,
Patient Service Center, POB (Physician Office Building Ste 155) and ask to have
your blood drawn for the Speer Lab Study. A copy of your Informed Consent Form
will be mailed to you at the address you provide on the Dynacare form.
Sincerely,
Dr. Mark Anderson M.D.

Figure 9: Cover letter for Crohn’s volunteers
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Detection of Mycobacteria paratuberculosis Antibodies in Crohn’s
Patient Serum.
Dr. C.A. Speer Ph.D.
Dr. Shigetoshi Eda Ph.D.
Forestry, Wildlife and Fisheries
University of Tennessee
274 Ellington Plant Science
Knoxville, Tn 37996
Dr. Mark Anderson M.D.
1928 Alcoa Highway
Medical Office Building B, Suite 100
Knoxville,TN 37920
The study in which I am being asked to participate by your Gastroenterologist Dr. Mark
Anderson has the goal of producing a quick and accurate test for Crohn’s Disease (CD).
It has been shown by some investigators that most CD patients have serum antibodies
against a bacterium, called Mycobacterium paratuberculosis, which may be involved in
CD. We have developed a method to detect such antibodies with high sensitivity and
specificity, and the method requires only a one time blood draw of 5 to 10 mls from
patients with CD. UT medical center’s phlebotomy lab [University of Tennessee, Patient
Service Center, POB (Physician Office Building Ste 155)] will draw a little more than a
tablespoon of your blood, the procedure should take less than 15 minutes, there is a
possibility some redness or swelling could occur. If redness and swelling do occur they
will not last long. This is a preliminary study involving 20 to 40 subjects; if the initial
findings are promising more Crohn’s patients will be enrolled. Further efforts on the
development of a diagnostic test for CD based on our method would benefit CD patients
by possibly providing more accurate diagnosis and by reducing risk, cost, and time
required for diagnosis.
I have read the description of the study and I have freely volunteered to participate. I
understand that I do not have to take part in this study and that my refusal to participate
will involve no penalty or loss of rights to which I am entitled and it will not adversely
affect my subsequent medical care. I have had an opportunity to ask questions of the
doctor and have received acceptable answers. I understand that I will receive the same
treatment for my condition weather I participate in the study or chose not to participate.
No treatment decision will be made from the results of the tests.
There is no additional medical cost to me or my insurance involved for the test, all
expenses will be paid for by Dr. Speer’s lab through The University of Tennessee,
Institute of Agriculture. My Blood will be drawn by Dynacare a UT contracted
phlebotomy lab, Dr. Speer will not be involved in any medical procedure.
1

Figure 10: Volunteer consent form
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Figure 10 continued

I understand that I am not waving any legal rights or releasing the hospital or its agents from
liability for negligence. I understand that in the event of physical injury resulting from the
research procedure, The University of Tennessee does not have funds budgeted for
compensation either for lost wages or for medical treatment. There is no additional medical
cost to me or my insurance involved for the test, all expenses will be paid for by Dr. Speer’s
lab at the University of Tennessee, Institute of Agriculture.
PATIENT CONFIDENTIALITY
Although study results may be published, your confidentiality will be maintained. Your name
or information identifying you will not be released without written permission unless required
by law. Under federal privacy regulations, you have the right to determine who has access
to your personal health information (called “protected health information” or PHI). PHI
collected in this study may include your medical history, the results of physical exams, lab
tests, x-ray exams, and other diagnostic and treatment procedures, as well as basic
demographic information. By signing this consent form, you are authorizing the researchers
at the University of Tennessee Medical Center to have access to your PHI collected in this
study and to receive your PHI from, Dr. Mark Anderson M.D., and the University of
Tennessee Medical Center where you have received health care. In addition, your PHI may
be shared with other persons involved in the conduct or oversight of this research, including
the (FDA) Food and Drug Administration, the University of Tennessee Medical Center, and
the University of Tennessee Graduate School of Medicine Institutional Review Board. Your
PHI will not be used or disclosed to any other person or entity, except as required by law, or
for authorized oversight of this research study by other regulatory agencies, or for other
research for which the use and disclosure of your PHI has been approved by the IRB. Your
PHI will be used indefinitely. You may cancel this authorization in writing at any time by
contacting the Principal Investigator listed on the first page of the consent form. If you
cancel the authorization, continued use of your PHI is permitted if it was obtained before the
cancellation and its use is necessary in completing the research. However, PHI collected
after your cancellation may not be used in the study. If you refuse to provide this
authorization, you will not be able to participate in the research study. If you cancel the
authorization, then you will be withdrawn from the study. Finally, the federal regulations
allow you to obtain access to your PHI collected or used in this study. However, in order to
complete the research, your access to this PHI may be temporarily suspended while the
research is in progress. When the study is completed, your right of access to this
information will be reinstated.

2
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Figure 10 continued
If you have any questions regarding this study, you may contact the Co-Principal
Investigators, Dr. C.A. Speer at 865-974-0467 or Dr. Shige Eda as well as the Study
Coordinator Cathy Scott at 865-974-0465. If you have any questions regarding your
health or risks associated with participating in the study you may contact your physician
Dr. Mark Anderson at 865-544-6570. If at any time you have any further questions about
your rights as a participant in this research protocol, you may contact the University of
Tennessee Graduate School of Medicine Institutional Review Board (a group of people
who review the research to protect your rights) at 865-544-9781. Thank you for your
consideration.
You will receive a copy of this consent form for your records.
______________________________
_________________________
Signature of Subject
Date
______________________________
_________________________
Signature of Principal Investigator
Date
.
Subject’s Age-___________________
Subject’s Gender- M or F
Dynacare- Draw two red top no additive vacutaner tubes of blood attach this form and
please call 974-0465 or 974-0479 immediately for sample pick up. Thanks.

3
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Bacterial Cultures
Whole-cell MAP
To culture MAP we used a Middlebrook broth that has become standard
for many mycobacteria since its discovery by Middlebrook et al. during the
1950’s [81, 82]. Specifically, Linda strain MAP (ATCC© 43015) was cultured in
Middlebrook 7H9 medium (Becton Dickinson, Cockeysville, Maryland) with
10% oleic acid, albumin, dextrose, and NaCl (OADC). This particular strain was
thought to be ideal for such a study as it had been originally isolated from the
intestinal mucosa of a 15 year-old Crohn’s patient named Linda [1]. Interestingly,
the strain was reactive to antibodies in sera obtained from JD-positive cattle in the
FCM assay as well [2]. Since mycobactin J is critical for the growth of MAP, 2
μg/ml of the iron chelator was added to the growth media [45]. Media were
prepared aseptically, with autoclaving for the M7H9/mycobactin J solution and
vacuum filtration for the OADC due to denaturing concerns under high
temperature conditions. In our previous work, we found that MAP bacilli were
not antigenic until they had been growing in media for at least 3 months. This
may be due to the slow-growing nature of MAP. Visible films of bacteria along
the bottommost region of the flask were a good visual indicator for proper growth
state. Periodic culture antigenicity assays were conducted to identify those
cultures which exhibited the strongest antibody reactivity to pooled samples of
JD-positive serum. Those with strong fluorescence using a JD-positive, and weak
to negligible fluorescence using the JD-negative pooled sera were chosen as
positive and negative controls for testing serum samples corrected from CD
patients.
MAP Spheroplasts
Spheroplasts or cell wall deficient (CWD) forms of MAP have been
isolated from CD patients, so it was important to examine if CWD forms of MAP
can be used to detect anti-MAP antibodies in CD patients [27]. In 2003, Hines et
al. successfully transformed a strain of MAP with a full cell wall to a CWD form
of MAP [83]. We, therefore, prepared CWD form of MAP (Linda strain)
according to their protocol with minor modifications. First we spun down 10 ml
of Linda strain MAP in a viable culture. The pelleted bacteria was then
resuspended in 20 ml of M7H( w/ OADC and glycerol) with additional 1%
glycine added. The solution was incubated for 3 days at 37ºC. A saline wash
followed with a subsequent treatment in a CWD solution that includes 1.2%
glycine, 30µL/ml lysozyme, 60% M7H9 w OADC, 40% 0.5M sucrose and 20mM
MgCl2. The bacteria were placed in the chemical bath for an eight day incubation
period. Post-incubation the CWD forms of MAP had to be examined quickly as
gross reversions to normal MAP can occur in as little as 8 days when treated
bacteria are placed back into nutrient rich environments like M7H9 broth [83].
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Yeasts
Several different strains of dried Saccharomyces cerevisiae were obtained
from a local brewer’s store and placed in nutrient broth for overnight culture.
Additionally an official strain of S. cerevisiae purchased from the ATCC©
(47058) was cultured in a same manner. Since yeasts are facultative anaerobes,
both aerobic and anaerobic culture conditions were applied and tested. A Candida
albicans culture was obtained from Dr. Pamela Small, a Professor in
Microbiology at the University of Tennessee, Knoxville.
Other Bacteria
Escherichia coli was purchased from ATCC© (23258 ) and cultured
overnight in nutrient broth. This strain was isolated from the urine of a human
patient. Streptococcus faecalis (ATCC© 19433) was cultured anaerobically
overnight in brain heart infusion broth. Streptococcus gallolyticus (ATCC© 9809)
was cultured in trypticase soy broth with defibrinated sheep blood under aerobic
conditions. A human isolate of Salmonella typhimurium (ATCC© 1311) was
cultured aerobically in nutrient broth. Yersinia enterocolitica (ATCC© 23715)
was grown aerobically in tryptose broth. Clostridium difficile (ATCC© 43600)
isolated from the feces of a patient with colitis was cultured in reinforced
Clostridial broth in anaerobic conditions. Campylobacter jejejuni subsp. jejuni
(ATCC© 33291) isolated from human feces was cultured in brucella broth with
0.16% agar in aerobic conditions. A human isolate of Listeria monocytogenes
(ATCC© 19115) was cultured in brain heart infusion broth in aerobic conditions.
A human isolate of Yersinia pseudotuberculosis (ATCC© 29910) was cultured in
nutrient broth in aerobic conditions. All cultures were checked for their
opaqueness (indicating growth) and examined under light microscopy to affirm
bacterial presence post-inoculation.

The FCM Procedure
Microorganisms harvested from liquid cultures were centrifuged to pellet
the organisms. The pellet was resuspended in Buffer A (PBS, 10% SuperBlock,
0.05% Tween) at a 1:1 ratio of the initial culture volume extracted. Using a
Nunc® 96-well microarray plate which had a conical wells for centrifugation
steps (Rochester, NY), 2µL of room temperature serum were introduced into the
each well. Pooled positive sera from JD+ farms and pooled negative sera from
JD- farms were used as positive and negative controls, respectively. Fetal Bovine
Serum (FBS) was also used as a negative control. Two wells were left completely
devoid of any serum to examine the level of non-specific (background) binding of
secondary antibody to the bacteria. All sera and controls were tested in duplicate
to ensure quality control. Next, 100µL of suspension was inoculated into each
well of a 96-well plate for a final serum-to-bacteria ratio of 1:50. The solution
was resuspended for proper mixing with the individual sera. The plate was then
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covered and placed upon a plate rocker for 1 hour to incubate. After the
incubation, each well was washed with Buffer A to remove any non-specific
antibody binding to the whole-cell bacteria. The washing steps consisted of three
principle parts. First, the plates were centrifuged at 3500 rpm and 20ºC for 10
minutes. This was done to move the heavier and stickier materials (the bacteria
and bound antibodies to the bottom of the well where they became pellet). Next,
we removed the supernatant using a suction apparatus. The remaining pellet was
resuspended in Buffer A. This procedure was repeated a second time to ensure
the proper removal of any unwanted, non-specific antibodies that may have been
left in the wells. A final centrifugation and suction step was completed to
prepare the samples for FITC tagging.
Following the washes, a secondary antibody (2’ Ab) was added to tag the
remaining bound antibody-bacterial complexes. Since it has been shown that
yeast can be a marker of disease when detecting both IgG and IgA, both
antibodies were probed for in many of the assays [20]. The FITC-labeled 2’ Ab
(Jackson Immunology, West Grove, PA) was diluted to 1:25 using Buffer A. The
96-well plates were covered with aluminum foil to prevent premature
photoexcitation of FITC during the second incubation period. Secondary
antibody reactions were carried out at room temperature for 1 hour on a rocker.
The complex was then diluted in 1 ml of PBS and run on the flow cytometer (LSR
II, BD bioscience, San Diego, CA). Detector voltages were set at 691 V for the
Forward Scatter detector, 307 V for the Side Scatter, and 550 V for the FITC
fluorescence detector. The side scatter threshold was set at 200 V one that has
been shown to preferentially select bacterium from surrounding materials.
Measurements were conducted over a cell count of 10,000 units. FITC
fluorescent intensity was recorded as a measure of antibody presence. This could
be visualized by the histogram recorded by the FCM software. A statistical
analysis of the histogram was also included. An example of one flow cytometry
histogram and complimentary analysis recorded during an assay designed to
detect antibodies to whole-cell yeast is shown in Figure 11.

Statistical Analysis
The CD and HC serological groups were compared by ANOVA using a
completely randomized design (SAS 2001). If the serological groups were found
to be significantly different with an α<0.05 then sensitivity and specificities were
calculated using fixed cut-off values. Cut-off values were estimated using the HC
serum values: the cut-off was defined as the mean of this HC population plus two
standard deviations. Points lying above the cut-off values within the CD-free
serum group were considered false positives. Specificity was calculated as (n false
positive / n all negatives) x 100%. Sera from the CD group that fell below the
cut-off were considered false negatives. Sensitivity was calculated as (n tested
positive / n all positives) x 100%. Occasionally, gender was analyzed in a similar
manner to that of disease-state to determine whether there were any differences in
reactivity based upon sex.
36

Figure 11: Example of the histogram and
other statistical data recorded by the FCM
equipment
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CHAPTER IV: Assay Results
MAP Results
Whole-cell MAP
Antibody (IgG and IgA) binding to MAP was observed in CD and HC
groups, whereas MAP (Linda Strain) treated only with 2’ Ab for IgG and IgA
(Figure 12 and 13) showed no preferential binding for either serum population
(both p>0.05). This was true for the Linda strain, and also for several other MAP
strains that we evaluated (data not shown). Further, absorbtion with another
related bacteria, M. phlei (which is commonly used to reduce antibody crossreactivity to other mycobacterium antigens in ELISA tests for CD), failed to
improve the differentiation between the sera groups (data not shown) [84].

Human Sera IgG binding to MAP
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Analysis of MAP using a IgG human antibody probe. There were no
significant differences between the two sera populations (p>0.05).

Figure 12: IgG FITC probe with MAP-Human Ab Complex
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Analysis of MAP using an IgA human antibody probe. There were no
significant differences between the two sera populations (p>0.05).

Figure 13: IgA FITC probe with MAP-Human Ab Complex
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Spheroplasts
The CWD form of MAP prepared in this study seemed to resemble the
spheroplasts’ rounder and slightly larger morphology described by Hines et al.
when observed under a light microscope [83]. Yet in our pilot experiments, the
spheroplasts failed to bind any antibody in either serum population.

OtherBacteria
Non-MAP Suspects
C. difficile, E. coli, C. jejuni, and S. faecalis all reacted strongly with
antibodies in the sera of both the HC and CD groups. Of these, C. difficile
resulted in the greatest level of antibody binding -- as indicated by the fluorescent
intensities that reached as high as 40,000 (unitless). However, while it appears
that these four bacteria showed some antibody binding, a differentiation of the
two sera groups was not possible using FCM (p>0.05). Our pilot studies with E.
coli and S. faecalis led us to evaluate the two bacteria in separate all-sera studies.
The results are shown in Figures 14 & 15.
Many of the non-MAP bacteria that we surveyed produced a very low
level of antibody binding. Non-MAP bacteria with little to no antibody response
included: L. monocytogenes, Y. entercolitica, and S. enterica. In these cases, the
bacteria in question failed to achieve fluorescence appreciably larger than that of
the 2’ antibody-only control.
Yeasts
S. cerevisiae differentiated the CD and HC sera groups with both IgG and
IgA (Figures 16 & 17; both p<0.05). Overall reactivity seemed to be higher in
those within the IgG assay, with FITC values with a mean FITC value of 25,449
within the CD group. The HC group in the IgG assay had a mean FITC
fluorescent value of 15,123. FCM analysis using IgA was the more successful of
the two assays.
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Human Sera IgG binding to E. coli
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Analysis of E. coli using a IgG human antibody probe. There were no
significant differences between the two sera populations (p>0.05).

Figure 14: IgG FITC probe with E. coli-Human Ab
complex
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Analysis of E. faecalis using a IgG human antibody probe. There were
no significant differences between the two sera populations (p>0.05).

Figure 15: IgG FITC probe with E. faecalis-Human Ab
complex
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Human Sera IgG binding to S. cerevisiae
IgG binding (fluorescent intensity)
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Analysis of Baker’s yeast using an IgG human antibody probe. Serum groups were significantly different (p<0.05). CD
mean = 25,449. HC mean = 15,123. At a CD cut-off of 33,151 sensitivity was 11/37 x 100% = 29.7% and specificity
was ((1-(1/37) x100% ) = 97.3%.

Figure 16: IgG FITC probe with S. cerevisiae-Human Ab complex
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Human Sera IgA binding to S. cerevisiae
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Analysis of Baker’s yeast using a IgA human antibody probe. CD and HC groups significantly different (p<0.05). CD
mean =4,325. HC mean =2,076. At a CD cut-off of 3,558 sensitivity was 13/37 x 100% = 35.1%. Specificity was
much higher than with IgG at ((1-(2/37)x100% ) = 95.0%

Figure 17: IgA FITC probe with S. cerevisiae -Human Ab complex
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sensitivity of 35.1%. This assay’s specificity was accurate to 95% (35/37). While
the IgG assay had a better specificity of 97.3% (36/37 HC controls were true
negatives), the tests’ sensitivity of 29.7% was slightly lower than that of its
counterpart. Further testing using 11 different strains of S. cerevisiae under both
aerobic and anaerobic conditions were unable to improve upon diagnostic
sensitivity (data not shown).
C. albicans w/ IgA (Figure 18) also differentiated the CD and HC sera
groups (p<0.05). There was significantly high reactivity within the CD group
with FITC values as high as 100,000. The FITC mean amongst the CD group was
30,939. The HC group had a mean FITC value of 16,878. Sensitivities for the C.
albicans FCM test was 24.1% (9/37 CD sera tested positive using our cut-off
value). This was the lowest of the FCM methods which were able to differentiate
serum populations. Specificity for this assay was 91.9% as 3 false negatives were
detected. In addition, there were no differences between gender as a
subpopulation of the disease groups (p>0.05).
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C. albicans probing for IgA
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Analysis of C. albicans using a IgA human antibody probe. CD and HC groups determined to
be significantly different (p<.05). CD mean determined to be 30,939. HC group mean found to
be 16,878. CD cut-off value determined to be at 49,486. Using this value sensitivity determined
to be 9/37 x 100% or 24.3%. Specificity was much lower than with IgG and determined to be
((1-(3/37)x100% ) or 91.9%

Figure 18: IgA FITC probe with C. albicans-Human
Ab complex
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CHAPTER V: Discussion
Summary of Results
The results of this study are summarized in Figure 19. While MAP were
unable to differentiate the CD and HC groups under various experimental
conditions, there were some encouraging aspects from our FCM studies using CD
and HC sera. Our study confirmed previous data obtained by many researchers
which showed a higher overall antibody reactivity to S. cerevisiae for CD subjects
when compared to healthy individuals. While our sensitivities were not as high
as some that have been reported, they approached those reported by Bossuyt in his
review of antibody markers of CD [21]. Similarly, C. albicans was able to
differentiate the sera populations supporting the common antigen association
discussed by Standaert-Vitse et al. [23].
Many bacteria reacted strongly, but did not elicit sufficient differentiation
to justify a full-length test. Lastly, many of the bacteria failed to elicit any
antibody binding whatsoever.
Discussion of MAP Non-differentiation
While there was certainly reactivity to MAPin our FCM, our MAP assays
did not allow for differentiation of the two sera groups. Few serological tests
probing for MAP antibodies have been applied to CD populations, but one large
population study by Bernstein et al. [34] revealed similar results our own.. Their
study used 283 CD sera, 144 UC sera, and 402 HC sera to look for antibodies to
MAP using a commercially available ELISA (IDEXX, Westbrook, ME) which
had been manufactured for use in dairy cattle tests, but had been validated for
human use as well. Its validation in humans may come into question, though, as
the positive control came from the pooled sera of a man who had accidentally
inoculated himself with a killed MAP vaccine and had incurred a gramulatous
legion at the injury site. Negative controls of well-studied American Cross
subjects who had no history of HC made up their control negative population to
allow them to obtain S/P ratios. A final strength of their study was that it used
CD and HC volunteers from Manitoba, Candida; a region with a very high CD
rate that coincides with high rate of MAP prevalence within the dairy cattle of the
agricultural town [33].
While there was a high rate of sera in Bernstein’s study which were
considered positive, these sera were spread across all sera groups with an
approximate overall seropositivity of 35%. The authors found no true statistical
difference between the two populations. To be exact the CD sera were 37.8%
positive while the HC group was 33.6% positive. Further, gender was unable to
predict disease, along with seven other variables which included predispositions
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Figure 19: Summary of results
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to MAP exposure that theauthors surveyed as MAP antibody-positive indicators.
Unlike Bernstein et al., we lacked a true positive control to set cut-off
values for the MAP FCM. Thus we cannot properly estimate the sensitivity and
specificity of our test. Yet, like the authors, we were also unable to detect a
antibody difference between the sera populations. Either we do not have the
correct antigen on our bacteria to elicit a differentiating response, or else MAP is
sufficiently common bacteria for both HC and CD subjects to have built-up some
antibody defense for it. In addition, the preabsorbtion experiments with M. phlei
were conducted to reduce potential cross-reactivity to other mycobacteria, but
perhaps another future experiment could be designed using preabsorbtion with
other mycobacterium. Two promising candidates would be be M. kansassi and
M. tuberculosis. Thayer et. al found many MAP seropositive CD subjects to also
be seropositive for these two mycobacteria [85]. Surprisingly, they found that
100% of CD subjects that were seropositive to MAP were also seropositive to M.
tuberculosis. In addition, 43% of CD subjects seropositive to MAP, were also
seropositive for M. kansassi.
The genetic susceptibility of certain patients to CD suggests that MAP
may need a G.I. system malfunction in order to invade and cause disease [5].
Presently, we lack the proper genetic information on our subjects to explore this
issue further. Other important information we lack is the disease history of the
CD subjects and their past treatment. These data might help to explain if there
has been a sufficient period of time for the subjects to develop a strong immune
response, or, in some cases, if disease has been ongoing for too long, so that
response has declined. This latter possibility is highlighted in a study conducted
by Olsen et al. in 2001 that compared the antibody titers to a MAP derived protein
in subjects with CD and UC [86]. While the CD subjects seemed to have an
overall higher antibody response to the MAP proteins, a peculiar thing had
occurred. It seemed that the longer the period had been since each CD subject
had been diagnosed with disease, the lower the antibody responses tended to be.
This negative correlation was very strong: rs= -0.85 [86].
A second patient history consideration we must take into account is what
type of treatment has been administered. For example it would have been useful
to know whether or not immunosuppressant therapy and possibly even
antimycobacterial medication had been administered to the CD patients.
Immunosuppressant would lower the entire immune system, including humoral
immunity. Although this treatment is usually reserved for subjects with severe CD
who don’t respond to other treatments [4], we cannot rule out the possibility that
our subjects were on immunosuppresants.
Our findings provide no affirmation of MAP’s possible role in CD
via serological means, it would be premature to conclude that the mycobacterium
is not involved in any manner. Serological tests merely detect antibodies and thus
are considered an ‘indirect’ means of determining causation. Their presence,
even in high titers, does not directly imply active, ongoing infection. Our bodies
possess memory B-cells which continually produce antibodies to specific antigens
long after the body has cleared those antigens.
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As previously discussed, much of the literature describing actual MAP
within CD tissue has involved a CWD form [1]. Thus using assays designed to
detect antibodies against surface antigens of an intact bacteria (with an outer cell
wall) may be unlikely to produce a successful differentiation. Further, while we
did attempt to test for reactions to spheroplastic forms of MAP, it cannot be
assumed that this spheroplastic form is identical to that observed in vivo. As
Beran et al. note in their review of spheroplastic mycobacteria, no study has been
produced which reveals the in vivo behavior of these chemically-formed CWD
MAP [87]. Thus, further research is needed to better verify the in vivo behavior
exhibited chemically-induced spheroplastic so as to determine whether or not
treated bacteria are sufficient for this sort of assay. Secondly, spheroplastic
bacteria may lack the necessary antigens to induce an immune response in the
first place. To date, no study has directly investigated the antibody-inducing
ability of spheroplastic MAP. However, an extremely indirect evaluation of the
spheroplastic antibody induction ability was conducted in a very recent study
conducted by Hines et al. [88]. In this study the authors attempted to look for
antibodies to chemically-induced spheroplastic MAP vaccines in goat kids. The
MAP bacteria were treated in a similar manner to our experiments to induce the
spheroplastic form. The bacteria were then killed and injected into the animals to
evaluate vaccine effectiveness. The researchers utilized a commercial Parachek
® ELISA kit (Prionics, Zurich, Netherlands) to evaluate antibody responsiveness
pre and post-challenge with live whole-cell pelleted MAP. It is important to note
that this ELISA uses antigens removed by a 30 minute sonication. This step is
likely to remove all antigens, even the most basal ones which a CWD MAP might
possess. In their study, none of the CWD vaccines were able to induce an
appreciable humoral immune response.
The water is further clouded by numerous reports of serological data that
conflict with MAP DNA probe data. This suggests that there is a disconnect
between MAP presence within an individual, and the antibodies to that bacterium
that have been stockpiled by that person’s humoral immune response. This can be
evidenced by a study conducted by Collins et al. in which used 2 separate
diagnostic tests, that of PCR and that of the IDEXX© ELISA [89]. A subset of
their studies included a group of 181 individuals which consisted of HC, CD, and
UC subjects. Of these 36 were positive for MAP IS900 PCR. Another 11 were
positive for MAP antibodies by ELISA. However, in not a single instance was a
subject positive for both tests.
Lastly, the possibility exists that there is a strain of MAP which is
more infectious than others. If this was the case, it may elicit an entirely different
antibody response than those for the non-infectious MAP. Thus, while we may be
detecting an antibody response in both HC and CD subjects, antibodies to the
more infectious strain may have differentiated the populations. Different strains
of MAP may express unique surface antigens which have a complimentary set of
antibodies predominantly present in those with CD. This has been shown to be
the case with other bacteria such as Helicobacter pylori which had differential
antibody responses depending on strain type [90].
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Antibody Reactions in Non-MAP Bacteria
Of the non-MAP bacteria surveyed, 4 out of 9 had an appreciable antibody
response across all sera groups. One of the 4 non-reactive bacteria, S.
gallolyticus, simply failed to grow. The remaining three that failed to react may
have behaved this way because these are bacteria that are less common and thus
haven’t elicited a corresponding humoral immune response for those individuals
tested. For example, L. monocytogenes -- a gram-positive bacteria that can
survive refrigeration temperatures -- is more known for its role in a small
percentage of food poisoning cases than as a commensal human gut microbe [38].
Another, S. enterica subsp. typhimurium, is also being monitored carefully by the
CDC, even though it is considered to be part of the normal natural flora of the
human gut. Of the remaining 5 that did react, none were able to differentiate the
sera populations (p>0.05). High environmental exposure rate to these microbes
may have resulted in a generalized, high antibody titer that is common to both the
HC and CD groups.
Differentiating Populations Using Whole-cell Yeast FCM
Both of the yeast species that we used to investigate for unique antibody
responses were able to differentiate the CD and HC populations. Antibodies to S.
cerevisiae were much more acute in their differentiating achieving overall assay
sensitivities of 29.7% and 35.1% for IgG and IgA responses, respectively. While
one could look at the IgG responses and presume the two-fold higher FITC levels
to be indicative of different antibody levels to MAP according to immunoglobulin
type, this is not a safe assumption.
The finding that the yeasts were able to differentiate the two sera groups is
important because it proves that FCM can be a valuable means of detecting
differential antibody responses. It affirms studies by our lab, and by others, that
the flow cytometer is sensitive enough to detect minute microbe-antibody
complexes [2, 80]. In 2006, Reese et al. conducted a rigorous metaanalysis on
articles concerning serological markers within CD that included sifting through
hundreds of articles to obtain the highest quality studies on ASCA and pANCA
markers as predictors of disease [91]. Sixty studies were choosen for a detailed
statistical analysis. None of the articles dealt with differentiating CD from HC
populations, as the test is more commonly used to test CD from UC subjects.
One subgroup of articles compared IBD versus non-IBD groups using
ASCA IgA ELISAs, with an overall sensitivity of 31.4% obtained from a test
population of 1,651 subjects. This was very similar to the 35.1% sensitivity we
achieved when differentiating CD from HC groups using 74 subjects. A review
article detailing ASCA sensitivity and specificity information show our data to be
consistent with many of the lower-end sensitivity estimates (ranging from 4070%). [21]. If sensitivity for ASCAs could be improved for the FCM,
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technological advances in microfluidic flow cytometers would allow for quicker,
in-house tests to be conducted.
Antibodies to C. albicans were less apt to separate the sera
populations. These were the lowest assay sensitivities achieved by detecting only
9 of the 37 or 24.3% of the CD sera as positive. There are four common cell wall
macromolecules shared between S. cerevisiae and C. albicans [92]. These consist
of chitin, mannoproteins, β(1,6) glucan, and , β(1,3) glucan. Since these cell wall
constituents are expressed on the outer surface of both yeasts (albeit in different
concentrations), antibodies directed towards the entities are likely to cause a
cross-reactivity event. That is, antibodies directed towards the cell wall of S.
cerevisiae are also binding to that of C. albicans. As stated previously, this has
been proven as C. albicans has been shown to cause false positive results in the
ASCA test [23].
Final Thoughts
The experiments reported here represent a first attempt to utilize FCM to
improve CD diagnostics. Our previous success with the method in an animal
model made this attempt to apply FCM to human sera the logical next step.
Given our present lack of success, it is clear that the problem is not a simple one,
but it certainly seems worth continuing to pursue. Meanwhile, CD continues in
its enigmatic ways among the human population. There are those who feel that
the disease is strictly a bacterial issue and others who feel another mechanism
may be at the center of the cause – given the present state of knowledge, we
suggest the answer probably lies somewhere in between .

52

LIST OF REFERENCES

53

1.
Chiodini, R.J., et al., Characteristics of an unclassified Mycobacterium
species isolated from patients with Crohn's disease. J Clin Microbiol, 1984.
20(5): p. 966-71.
2.
Eda, S., et al., New method of serological testing for Mycobacterium
avium subsp. paratuberculosis (Johne's disease) by flow cytometry. Foodborne
Pathog Dis, 2005. 2(3): p. 250-62.
3.
Crohn, B.B., L. Ginzburg, and G.D. Oppenheimer, Regional ileitis; a
pathologic and clinical entity. Am J Med, 1952. 13(5): p. 583-90.
4.
America, C.s.a.C.F.o., About Crohn's Disease. 2007, Crohn's and Colitis
Foundation of America: New York.
5.
Chacon, O., L.E. Bermudez, and R.G. Barletta, Johne's disease,
inflammatory bowel disease, and Mycobacterium paratuberculosis. Annu Rev
Microbiol, 2004. 58: p. 329-63.
6.
Bayless, T., et al., Crohn's Disease, in Introduction. 2007, The Johns
Hopkins Medical Institutions: Gastroenterology and Hepatology Resource
Center: Baltimore.
7.
Weinstock, J.V., Crohn's Disease, in Granulomatous Infections and
Inflammations: Cellular and Molecular Mechanisms, D.L. Boros, Editor. 2003,
ASM Press: Washington, D.C.
8.America, C.s.a.C.F.o., About Crohn's Disease. 2007, Crohn's and Colitis
Foundation of America: New York.
9.
Grant, I.R., Zoonotic potential of Mycobacterium avium ssp.
paratuberculosis: the current position. Journal of Applied Microbiology, 2005.
98(10): p. 1282-1293.
10.
Hisamatsu, T., et al., CARD15/NOD2 functions as an antibacterial factor
in human intestinal epithelial cells. Gastroenterology, 2003. 124(4): p. 993-1000.
11.
Liu, Y., et al., Immunocytochemical evidence of Listeria, Escherichia coli,
and Streptococcus antigens in Crohn's disease. Gastroenterology, 1995. 108(5):
p. 1396-404.
12.
Blaser, M.J., et al., Patients with active Crohn's disease have elevated
serum antibodies to antigens of seven enteric bacterial pathogens.
Gastroenterology, 1984. 87(4): p. 888-94.
13.
Cartun, R.W., et al., An immunocytochemical search for infectious agents
in Crohn's disease. Mod Pathol, 1993. 6(2): p. 212-9.
14.
Tabaqchali, S., D.P. O'Donoghue, and K.A. Bettelheim, Escherichia coli
antibodies in patients with inflammatory bowel disease. Gut, 1978. 19(2): p. 10813.
15.
Weber, P., et al., Microbic superinfection in relapse of inflammatory
bowel disease. J Clin Gastroenterol, 1992. 14(4): p. 302-8.
16.
Keighley, M.R., et al., Clostridium difficile toxin in acute diarrhoea
complicating inflammatory bowel disease. Gut, 1982. 23(5): p. 410-4.
54

17.
Saebo, A., et al., Inflammatory bowel disease associated with Yersinia
enterocolitica O:3 infection. Eur J Intern Med, 2005. 16(3): p. 176-182.
18.
Berberian, L.S., et al., Expression of a novel autoantibody defined by the
VH3-15 gene in inflammatory bowel disease and Campylobacter jejuni
enterocolitis. J Immunol, 1994. 153(8): p. 3756-63.
19.
Homewood, R., et al., Ileitis due to Yersinia pseudotuberculosis in Crohn's
disease. J Infect, 2003. 47(4): p. 328-32.
20.
Main, J., et al., Antibody to Saccharomyces cerevisiae (bakers' yeast) in
Crohn's disease. Bmj, 1988. 297(6656): p. 1105-6.
21.
Bossuyt, X., Serologic markers in inflammatory bowel disease. Clin Chem,
2006. 52(2): p. 171-81.
22.
Preda, C.M., et al., Significance of anti-sacharomices cerevisiae
antibodies (ASCA) in patients with inflammatory bowel diseases in Romania. Rom
J Gastroenterol, 2005. 14(1): p. 23-6.
23.
Standaert-Vitse, A., et al., Candida albicans is an immunogen for antiSaccharomyces cerevisiae antibody markers of Crohn's disease.
Gastroenterology, 2006. 130(6): p. 1764-75.
24.
Savage, N.W., et al., Serum and salivary IgA antibody responses to
Saccharomyces cerevisiae, Candida albicans and Streptococcus mutans in
orofacial granulomatosis and Crohn's disease. Clin Exp Immunol, 2004. 135(3):
p. 483-9.
25.
McKenzie, H., et al., Antibody to selected strains of Saccharomyces
cerevisiae (baker's and brewer's yeast) and Candida albicans in Crohn's disease.
Gut, 1990. 31(5): p. 536-8.
26.
McFadden, J.J., et al., Crohn's disease-isolated mycobacteria are
identical to Mycobacterium paratuberculosis, as determined by DNA probes that
distinguish between mycobacterial species. J Clin Microbiol, 1987. 25(5): p. 796801.
27.
Wall, S., et al., Identification of spheroplast-like agents isolated from
tissues of patients with Crohn's disease and control tissues by polymerase chain
reaction. J Clin Microbiol, 1993. 31(5): p. 1241-5.
28.
Chamberlin, W., et al., Review article: Mycobacterium avium subsp.
paratuberculosis as one cause of Crohn's disease. Aliment Pharmacol Ther, 2001.
15(3): p. 337-46.
29.
Sechi, L.A., et al., Identification of Mycobacterium avium subsp.
paratuberculosis in biopsy specimens from patients with Crohn's disease
identified by in situ hybridization. J Clin Microbiol, 2001. 39(12): p. 4514-7.
30.
Sechi, L.A., et al., Mycobacterium avium subsp. paratuberculosis, genetic
susceptibility to Crohn's disease, and Sardinians: the way ahead. J Clin
Microbiol, 2005. 43(10): p. 5275-7.
31.
Naser, S.A., et al., Culture of Mycobacterium avium subspecies
paratuberculosis from the blood of patients with Crohn's disease. Lancet, 2004.
364(9439): p. 1039-44.

55

32.
Naser, S.A., D. Schwartz, and I. Shafran, Isolation of Mycobacterium
avium subsp paratuberculosis from breast milk of Crohn's disease patients. Am J
Gastroenterol, 2000. 95(4): p. 1094-5.
33.
Bernstein, C.N., et al., Population-based case control study of
seroprevalence of Mycobacterium paratuberculosis in patients with Crohn's
disease and ulcerative colitis. J Clin Microbiol, 2004. 42(3): p. 1129-35.
34.
El-Zaatari, F.A., et al., Characterization of Mycobacterium
paratuberculosis p36 antigen and its seroreactivities in Crohn's disease. Curr
Microbiol, 1999. 39(2): p. 115-9.
35.
El-Zaatari, F.A., M.S. Osato, and D.Y. Graham, Etiology of Crohn's
disease: the role of Mycobacterium avium paratuberculosis. Trends Mol Med,
2001. 7(6): p. 247-52.
36.
Grant, I.R., Rowe, Michael T, Dundee, Louise and Edward Hitchings,
Mycobacterium avium ssp.paratuberculosis: its incidence, heat resistance and
detection in milk and dairy products. International Journal of Dairy Technology,
2001. 54(1): p. 2-14.
37.
Li, L., et al., The complete genome sequence of Mycobacterium avium
subspecies paratuberculosis. Proc Natl Acad Sci U S A, 2005. 102(35): p. 123449.
38.
Madigan, M.T., Martinko, John M. and Jack Parker, Brock Biology of
Microorganisms. 10th ed, ed. G. Carlson. 2003, London: Prentice Hall.
39.
Alteri, C.J., et al., Mycobacterium tuberculosis produces pili during
human infection. Proc Natl Acad Sci U S A, 2007. 104(12): p. 5145-50.
40.
Rogall, T., et al., Towards a phylogeny and definition of species at the
molecular level within the genus Mycobacterium. Int J Syst Bacteriol, 1990.
40(4): p. 323-30.
41.
Harris, J.E. and A.M. Lammerding, Crohn's disease and Mycobacterium
avium subsp. paratuberculosis: current issues. J Food Prot, 2001. 64(12): p.
2103-10.
42.
Manning, E.J., Mycobacterium avium subspecies paratuberculosis: a
review of current knowledge. J Zoo Wildl Med, 2001. 32(3): p. 293-304.
43.
Bannantine, J.P., et al., Genomic homogeneity between Mycobacterium
avium subsp. avium and Mycobacterium avium subsp. paratuberculosis belies
their divergent growth rates. BMC Microbiol, 2003. 3: p. 10.
44.
Takewaki, S., et al., Nucleotide sequence comparison of the mycobacterial
dnaJ gene and PCR-restriction fragment length polymorphism analysis for
identification of mycobacterial species. Int J Syst Bacteriol, 1994. 44(1): p. 15966.
45.
Harris, N.B. and R.G. Barletta, Mycobacterium avium subsp.
paratuberculosis in Veterinary Medicine. Clin Microbiol Rev, 2001. 14(3): p.
489-512.
46.
De Voss, J.J., et al., Iron acquisition and metabolism by mycobacteria. J
Bacteriol, 1999. 181(15): p. 4443-51.

56

47.
Marsh, I.B., et al., Genomic comparison of Mycobacterium avium subsp.
paratuberculosis sheep and cattle strains by microarray hybridization. J
Bacteriol, 2006. 188(6): p. 2290-3.
48.
Semret, M., C.Y. Turenne, and M.A. Behr, Insertion sequence IS900
revisited. J Clin Microbiol, 2006. 44(3): p. 1081-3.
49.
Baumgartner, W. and J.L. Khol, Paratuberculosis (Johne's Disease) in
Ruminants-An Ongoing Story. Slov Vet Res, 2006. 43(1): p. 5-10.
50.
Matthews, P.R. and A. Sargent, The isolation of Mycobacteria from the
brown hare (Lepus europaeus). Br Vet J, 1977. 133(4): p. 399-404.
51.
Kennedy, D.J. and G. Benedictus, Control of Mycobacterium avium subsp.
paratuberculosis infection in agricultural species. Rev Sci Tech, 2001. 20(1): p.
151-79.
52.
Whittington, R.J. and E.S. Sergeant, Progress towards understanding the
spread, detection and control of Mycobacterium avium subsp paratuberculosis in
animal populations. Aust Vet J, 2001. 79(4): p. 267-78.
53.
Coussens, P.M., Mycobacterium paratuberculosis and the bovine immune
system. Anim Health Res Rev, 2001. 2(2): p. 141-61.
54.
Emery, D.L. and R.J. Whittington, An evaluation of mycophage therapy,
chemotherapy and vaccination for control of Mycobacterium avium subsp.
paratuberculosis infection. Vet Microbiol, 2004. 104(3-4): p. 143-55.
55.
Linnabary, R.D., Meerdink, G. L., Collins, M. T., Stabel, J. R., Sweeney, R.
W., Washington, M. K., Wells, S. J., Chiodini, R. J., Hansen, D., and Whitlock, R.
H., Johne's disease in cattle. Council for Agricultural Science and Technology,
2001. 17: p. 1-10.
56.
Sweeney, R.W., et al., Isolation of Mycobacterium paratuberculosis after
oral inoculation in uninfected cattle. Am J Vet Res, 1992. 53(8): p. 1312-4.
57.
Whitlock, R.H. and A.E. Rosenberger. Fecal culture protocol for
Mycobacterium paratuberculosis. A recommended procedure. in Proc. Ann.
Meeting US Anim. Hlth. Associ. 1990.
58.
Abbas, B. and H.P. Riemann, IgG, IgM and IgA in the serum of cattle
naturally infected with Mycobacterium paratuberculosis. Comp Immunol
Microbiol Infect Dis, 1988. 11(3-4): p. 171-5.
59.
Stabel, J.R., Transitions in immune responses to Mycobacterium
paratuberculosis. Vet Microbiol, 2000. 77(3-4): p. 465-73.
60.
Koets, A.P., et al., Differential changes in heat shock protein-,
lipoarabinomannan-, and purified protein derivative-specific immunoglobulin G1
and G2 isotype responses during bovine Mycobacterium avium subsp.
paratuberculosis infection. Infect Immun, 2001. 69(3): p. 1492-8.
61.
Sockett, D.C., et al., Evaluation of four serological tests for bovine
paratuberculosis. J Clin Microbiol, 1992. 30(5): p. 1134-9.
62.
Whittington, R.J., G.J. Eamens, and D.V. Cousins, Specificity of absorbed
ELISA and agar gel immuno-diffusion tests for paratuberculosis in goats with
observations about use of these tests in infected goats. Aust Vet J, 2003. 81(1-2):
p. 71-5.
57

63.
Sergeant, E.S., et al., Evaluation of an absorbed ELISA and an agar-gel
immuno-diffusion test for ovine paratuberculosis in sheep in Australia. Prev Vet
Med, 2003. 61(4): p. 235-48.
64.
Collins, M., and Elizabeth Manning, History, in Johne's Disease
Information Center. 1996, University of Wisconsin-Madison, School of Veterinary
Medicine.
65.
Goldsby, R.A., Kindt, Thomas J, Osborne, Barbara A, and Janis Kuby,
Immunology. 5th ed. 2003, New York: W.H. Feeman and Company.
66.
Yokomizo, Y., R.S. Merkal, and P.A. Lyle, Enzyme-linked immunosorbent
assay for detection of bovine immunoglobulin G1 antibody to a protoplasmic
antigen of Mycobacterium paratuberculosis. Am J Vet Res, 1983. 44(11): p. 22057.
67.
Yokomizo, Y., H. Yugi, and R.S. Merkal, A method for avoiding falsepositive reactions in an enzyme-linked immunosorbent assay (ELISA) for the
diagnosis of bovine paratuberculosis. Nippon Juigaku Zasshi, 1985. 47(1): p.
111-9.
68.
Jark, U., et al., Development of an ELISA technique for serodiagnosis of
bovine paratuberculosis. Vet Microbiol, 1997. 57(2-3): p. 189-98.
69.
Eda, S., et al., A highly sensitive and subspecies-specific surface antigen
enzyme- linked immunosorbent assay for diagnosis of Johne's disease. Clin
Vaccine Immunol, 2006. 13(8): p. 837-44.
70.
Shin, S.J., et al., Comparative antibody response of five recombinant
antigens in related to bacterial shedding levels and development of serological
diagnosis based on 35 kDa antigen for Mycobacterium avium subsp.
paratuberculosis. J Vet Sci, 2004. 5(2): p. 111-7.
71.
Speer, C.A., et al., A novel enzyme-linked immunosorbent assay for
diagnosis of Mycobacterium avium subsp. paratuberculosis infections (Johne's
Disease) in cattle. Clin Vaccine Immunol, 2006. 13(5): p. 535-40.
72.
Kreuzpaintner, G., et al., Effect of intestinal resection on serum antibodies
to the mycobacterial 45/48 kilodalton doublet antigen in Crohn's disease. Gut,
1995. 37(3): p. 361-6.
73.
Steinkamp, J.A., Flow cytometry. Rev. Sci. Instrum., 1984. 55(9): p. 13751400.
74.
Davey, H.M. and D.B. Kell, Flow cytometry and cell sorting of
heterogeneous microbial populations: the importance of single-cell analyses.
Microbiol Rev, 1996. 60(4): p. 641-96.
75.
Fulwyler, M.J., Electronic separation of biological cells by volume.
Science, 1965. 150(698): p. 910-1.
76.
Hutter, K.J. and H.E. Eipel, Flow cytometric determinations of cellular
substances in algae, bacteria, moulds and yeasts. Antonie Van Leeuwenhoek,
1978. 44(3-4): p. 269-82.
77.
Steen, H.B. and T. Lindmo, Flow cytometry: a high-resolution instrument
for everyone. Science, 1979. 204(4391): p. 403-4.
78.
Soini, E. and I. Hemmila, Fluoroimmunoassay: present status and key
problems. Clin Chem, 1979. 25(3): p. 353-61.
58

79.
Crissman, H.A. and J.A. Steinkamp, Rapid, simultaneous measurement of
DNA, protein, and cell volume in single cells from large mammalian cell
populations. J Cell Biol, 1973. 59(3): p. 766-71.
80.
Dietrich, M.A., et al., Measurement of antibody binding to intact bacteria
using flow cytometric techniques. Journal of Microbiological Methods, 1991.
13(4): p. 281-292.
81.
Cohn, M.L., et al., Studies on isoniazid and tubercle bacilli. I. The
isolation of isoniazid-resistant mutants in vitro. Am Rev Tuberc, 1954. 70(3): p.
465-75.
82.
Middlebrook, G. and M.L. Cohn, Bacteriology of tuberculosis: laboratory
methods. Am J Public Health, 1958. 48(7): p. 844-53.
83.
Hines, M.E., 2nd and E.L. Styer, Preliminary characterization of
chemically generated Mycobacterium avium subsp. paratuberculosis cell wall
deficient forms (spheroplasts). Vet Microbiol, 2003. 95(4): p. 247-58.
84.
Suenaga, K., et al., Serum antibodies to Mycobacterium paratuberculosis
in patients with Crohn's disease. Dig Dis Sci, 1999. 44(6): p. 1202-7.
85.
Thayer, W.R., Jr., et al., Possible role of mycobacteria in inflammatory
bowel disease. II. Mycobacterial antibodies in Crohn's disease. Dig Dis Sci, 1984.
29(12): p. 1080-5.
86.
Olsen, I., et al., Elevated antibody responses in patients with Crohn's
disease against a 14-kDa secreted protein purified from Mycobacterium avium
subsp. paratuberculosis. Scand J Immunol, 2001. 53(2): p. 198-203.
87.
Beran, V., et al., Cell wall deficient forms of mycobacteria: a review, in
Veterianarni Medicina. 2006. p. 365-389.
88.
Hines, M.E., 2nd, et al., Efficacy of spheroplastic and cell-wall competent
vaccines for Mycobacterium avium subsp. paratuberculosis in experimentallychallenged baby goats. Vet Microbiol, 2007. 120(3-4): p. 261-83.
89.
Collins, M.T., et al., Results of multiple diagnostic tests for
Mycobacterium avium subsp. paratuberculosis in patients with inflammatory
bowel disease and in controls. J Clin Microbiol, 2000. 38(12): p. 4373-81.
90.
Pineros, D.M., et al., Helicobacter pylori in gastric cancer and peptic
ulcer disease in a Colombian population. Strain heterogeneity and antibody
profiles. Helicobacter, 2001. 6(3): p. 199-206.
91.
Reese, G.E., et al., Diagnostic precision of anti-Saccharomyces cerevisiae
antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory
bowel disease. Am J Gastroenterol, 2006. 101(10): p. 2410-22.
92.
Vink, E., et al., An in vitro assay for (1 --> 6)-beta-D-glucan synthesis in
Saccharomyces cerevisiae. Yeast, 2004. 21(13): p. 1121-31.

59

VITA
Taylor Fielden was born in Maryville, TN. He spent most of his life in
Tennessee enjoying the wildlife of the mountains and country. His time at
Maryville High School saw Taylor pursuing both his scientific curiosities and his
interest in writing within a variety of disciplines. Taylor attended Oglethorpe
University in the Fall of 2000 on a scholarship and began studies for a premedical path. Taylor transferred to the University of Tennessee in the Spring of
2002 and received his Bachelor’s of Science in Biological Sciences with a
concentration in Microbiology. Throughout his studies, Taylor has maintained a
healthy fascination with the natural world from the microscopic to the
macroscopic.

60

